ondansetron has been researched along with Pregnancy in 168 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Pregnancy: The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study's purpose was to determine if ondansetron can prevent pruritus after administration of intrathecal morphine in children, as has been demonstrated in adults." | 9.51 | Intravenous ondansetron reduced nausea but not pruritus following intrathecal morphine in children: Interim results of a randomized, double-blinded, placebo-control trial. ( Hong, RA; Leis, A; Li, Y; Malviya, S; Park, JM; Putnam, EM, 2022) |
| " The EMPOWER (EMesis in Pregnancy – Ondansetron With mEtoClopRamide) trial aimed to compare the clinical effectiveness and cost-effectiveness of two anti-sickness drugs [metoclopramide (metoclopramide hydrochloride, Actavis UK Ltd, Barnstable, UK; IV Ratiopharm GmbH, Ulm, Germany) and ondansetron (ondansetron hydrochloride dehydrate, Wockhardt UK Ltd, Wrexham, UK; IV Hameln Pharma plus GmbH, Hameln)] for the treatment of nausea and vomiting in pregnancy." | 9.41 | Ondansetron and metoclopramide as second-line antiemetics in women with nausea and vomiting in pregnancy: the EMPOWER pilot factorial RCT. ( Campbell, I; Fernandez-Garcia, C; Goudie, N; Graham, R; Howel, D; Lie, M; McColl, E; McParlin, C; Mossop, H; Nadeem, A; Nelson-Piercy, C; O'Hara, ME; Phillipson, J; Robson, S; Shehmar, M; Simpson, N; Steel, A; Ternent, L; Tuffnell, D; Williams, R, 2021) |
| "Although ondansetron was considered to prevent post-anesthesia shivering during cesarean section, its efficiency remained controversial." | 9.41 | A meta-analysis of randomized controlled trials: efficiency and safety of ondansetron in preventing post-anesthesia shivering during cesarean section. ( Cao, F; Chen, C; Liu, J; Zhang, J; Zhang, L; Zheng, G, 2023) |
| "Based on the results of this study, ondansetron had a significant effect on the alleviation of postoperative nausea and vomiting, as compared to dexamethasone in C-section surgical candidates." | 9.41 | Comparison of the Effects of Dexamethasone and Ondansetron on the Reduction of Postoperative Nausea and Vomiting following Cesarean Section under Spinal Anesthesia. ( Birjandi, M; Karimi, A; Nejadi, JR; Ronasi, N; Shamseh, M, 2021) |
| "This study aimed to determine whether gabapentin is more effective than standard-of-care therapy for treating hyperemesis gravidarum." | 9.41 | Effect of gabapentin on hyperemesis gravidarum: a double-blind, randomized controlled trial. ( Guttuso, T; Messing, S; Mullin, P; Saha, S; Shepherd, R; Strittmatter, C; Thornburg, LL; Tu, X, 2021) |
| "The objective of this randomised, double blinded clinical trial was to evaluate the efficacy of prophylactic administration of 4 mg ondansetron as monotherapy versus combination therapy of 4 mg ondansetron plus 8 mg dexamethasone for the prevention of intrathecal morphine-associated pruritus in caesarean section within 24 h." | 9.41 | Ondansetron versus ondansetron with dexamethasone to prevent intrathecal-morphine pruritus for caesarean patients: randomised double-blind trial. ( Ankouni, T; El Hassan, J; El Khatib, R; Itani, SE; Kanawati, S; Naja, Z; Rajab, O, 2021) |
| "Ondansetron has been shown to reduce the incidence of hypotension and vasopressor requirement during spinal anesthesia for obstetric and nonobstetric surgery." | 9.34 | A Prospective, Randomized, Double-Blinded Study of the Effect of Intravenous Ondansetron on the Effective Dose in 50% of Subjects of Prophylactic Phenylephrine Infusions for Preventing Spinal Anesthesia-Induced Hypotension During Cesarean Delivery. ( Chang, X; Chen, X; Ngan Kee, WD; Shen, H; Wei, C; Xiao, F; Xue, L; Zhang, Y, 2020) |
| " One hundred and eighty pregnant women referred to secondary care for hyperemesis gravidarum will be randomly allocated to 14-day treatment with either mirtazapine, ondansetron or placebo." | 9.34 | Validating the effect of Ondansetron and Mirtazapine In Treating hyperemesis gravidarum (VOMIT): protocol for a randomised placebo-controlled trial. ( Andersen, JT; Futtrup, TB; Jensen, AK; Løkkegaard, ECL; Ostenfeld, A; Pedersen, LH; Petersen, TS; Westergaard, HB, 2020) |
| "There was controversy about ondansetron can reduce the incidence of spinal-induced hypotension and decrease the consumption of vasopressor in cesarean delivery with spinal anesthesia." | 9.34 | Does an Earlier or Late Intravenous Injection of Ondansetron Affect the Dose of Phenylephrine Needed to Prevent Spinal-Anesthesia Induced Hypotension in Cesarean Sections? ( Liu, L; Qian, J; Xiao, F; Zheng, X, 2020) |
| "The weight-based dosing of ondansetron to reduce hypotension has never been investigated." | 9.27 | Minimal effective weight-based dosing of ondansetron to reduce hypotension in cesarean section under spinal anesthesia: a randomized controlled superiority trial. ( Dilokrattanaphijit, N; Karnjanawanichkul, O; Kunapaisal, T; Leeratiwong, J; Oofuvong, M, 2018) |
| "To evaluate the effect of prophylactic ondansetron on spinal anesthesia-induced hypotension and bradycardia among patients undergoing elective cesarean deliveries." | 9.22 | Randomized controlled trial comparing ondansetron and placebo for the reduction of spinal anesthesia-induced hypotension during elective cesarean delivery in Egypt. ( El Khouly, NI; Meligy, AM, 2016) |
| "Ondansetron is the drug of choice to prevent nausea in women undergoing cesarean surgery and can be used to prevent neonatal abstinence syndrome (NAS)." | 9.20 | Ondansetron pharmacokinetics in pregnant women and neonates: towards a new treatment for neonatal abstinence syndrome. ( Carvalho, B; Clavijo, C; Drover, DR; Elkomy, MH; Galinkin, JL; Peltz, G; Sultan, P; Wu, M, 2015) |
| "Prophylactic administration of ondansetron to parturients receiving intrathecal morphine for post-operative analgesia provides a significant reduction of intrathecal morphine-induced pruritus and nausea and vomiting." | 9.20 | Prophylactic administration of ondansetron in prevention of intrathecal morphine-induced pruritus and post-operative nausea and vomiting in patients undergoing caesarean section. ( Dongol, Y; Gurung, BS; Koju, RB, 2015) |
| "Maternal hypotension and nausea were significantly lower in ondansetron-treated patients versus placebo (p = 0." | 9.19 | Ondansetron preloading with crystalloid infusion reduces maternal hypotension during cesarean delivery. ( Shen, MK; Wang, M; Wang, Q; Yu, JJ; Yu, YY; Zhuo, L, 2014) |
| "To compare ondansetron with metoclopramide in the treatment of hyperemesis gravidarum." | 9.19 | Ondansetron compared with metoclopramide for hyperemesis gravidarum: a randomized controlled trial. ( Abas, MN; Azmi, N; Omar, SZ; Tan, PC, 2014) |
| "Healthy paturients undergoing cesarean delivery with intrathecal morphine 250μg and fentanyl 25μg were randomized to receive: prophylaxis (ondansetron 8mg at cord clamping, normal saline 4mL for treatment of pruritus in the post-anaesthesia care unit); treatment (normal saline 4mL at cord clamping, ondansetron 8mg as required in the post-anesthesia care unit) or control (normal saline 4mL in both)." | 9.19 | Prevention versus treatment of intrathecal morphine-induced pruritus with ondansetron. ( Hess, P; Kung, AT; Li, Y; Pratt, S; Vasudevan, A; Yang, X, 2014) |
| "Our investigation showed ondansetron to be superior to the combination of pyridoxine and doxylamine in the treatment of nausea and emesis in pregnancy." | 9.19 | Ondansetron compared with doxylamine and pyridoxine for treatment of nausea in pregnancy: a randomized controlled trial. ( Capp, SM; Carstairs, SD; Oliveira, LG; Riffenburgh, RH; You, WB, 2014) |
| "Ondansetron 4 mg, given intravenously 5 min before subarachnoid block reduced hypotension and vasopressor use in parturients undergoing elective caesarean section." | 9.16 | Reduction in spinal-induced hypotension with ondansetron in parturients undergoing caesarean section: a double-blind randomised, placebo-controlled study. ( Goswami, A; Hazra, A; Sahoo, T; SenDasgupta, C, 2012) |
| "Ondansetron is effective for the treatment of intrathecal morphine-induced pruritus." | 9.14 | A randomized controlled trial of pentazocine versus ondansetron for the treatment of intrathecal morphine-induced pruritus in patients undergoing cesarean delivery. ( Charuluxananan, S; Patumanond, J; Punjasawadwong, Y; Sriprajittichai, P; Tamdee, D; Tawichasri, C, 2009) |
| " reduces the severity of pruritus and the use of rescue anti-pruritic medication, and improves satisfaction but does not reduce the overall incidence of pruritus in women who have received subarachnoid morphine 150 microg compared to ondansetron 8 mg i." | 9.14 | Reduction of severity of pruritus after elective caesarean section under spinal anaesthesia with subarachnoid morphine: a randomised comparison of prophylactic granisetron and ondansetron. ( Carey, M; Choroszczak, P; Immani, S; Ojo, R; Tan, T, 2010) |
| "Ondansetron is as effective as diphenhydramine in relieving pruritus caused by SA morphine in patients undergoing a cesarean delivery." | 9.14 | Ondansetron is as effective as diphenhydramine for treatment of morphine-induced pruritus after cesarean delivery. ( Adham, AM; Aouad, MT; Dagher, CM; Saasouh, WA; Siddik-Sayyid, SM; Yazbeck-Karam, VG; Zahreddine, BW, 2010) |
| "To study the association between ondansetron exposure during pregnancy and the risks of spontaneous abortion, stillbirth, and major congenital malformations." | 9.12 | Comparison of Pregnancy Outcomes of Patients Treated With Ondansetron vs Alternative Antiemetic Medications in a Multinational, Population-Based Cohort. ( Dahl, M; Dormuth, CR; Filion, KB; Fisher, A; Lu, X; Ma, Z; Moriello, C; Paterson, JM; Platt, RW; Raymond, CB; Reynier, P; Suissa, S; Winquist, B; Wu, F; Zhang, J, 2021) |
| "Neither ondansetron nor tropisetron prevent itching caused by intrathecal morphine with fentanyl." | 9.12 | Ondansetron and tropisetron do not prevent intraspinal morphine- and fentanyl-induced pruritus in elective cesarean delivery. ( Halonen, PM; Kainu, JP; Korttila, KT; Sarvela, PJ; Soikkeli, AI, 2006) |
| " Forty-one patients who requested surgical termination of pregnancy at the first trimester were administered three doses of ondansetron 8 mg before surgery." | 9.12 | Placental transfer of ondansetron during early human pregnancy. ( Chan, MT; Lau, TK; Siu, SS, 2006) |
| "We compared the efficacy of granisetron and ondansetron for the prevention of subarachnoid morphine-induced pruritus after cesarean delivery." | 9.12 | Does ondansetron or granisetron prevent subarachnoid morphine-induced pruritus after cesarean delivery? ( Aouad, MT; Azar, MS; Baraka, AS; Hakki, MA; Kaddoum, RN; Nasr, VG; Siddik-Sayyid, SM; Taha, SK; Yazbek, VG, 2007) |
| "In this randomized, double-blind study, we aimed to compare the effectiveness of lornoxicam and ondansetron for the prevention of intrathecal fentanyl-induced pruritus in patients undergoing cesarean section." | 9.12 | Lornoxicam and ondansetron for the prevention of intrathecal fentanyl-induced pruritus. ( Begec, Z; Erdil, FA; Ersoy, MO; Gedik, E; Gulhas, N; Sagir, O; Togal, T, 2007) |
| " The incidence of pruritus and nausea was significantly lower in the epidural ondansetron group than in the intravenous ondansetron group at 24 and 48 h postoperatively." | 9.12 | Epidural ondansetron is more effective to prevent postoperative pruritus and nausea than intravenous ondansetron in elective cesarean delivery. ( Han, DW; Hong, SW; Kim, KJ; Kwon, JY; Lee, JW, 2007) |
| "Fentanyl is commonly used for spinal analgesia during labour but it is associated with a high incidence of pruritus." | 9.11 | Intrathecal fentanyl-induced pruritus during labour: the effect of prophylactic ondansetron. ( Evans, SF; Paech, MJ; Wells, J, 2004) |
| "In this prospective, randomized, double-blinded study, we compared the prophylactic efficacy of nalbuphine and ondansetron for the prevention of intrathecal morphine-induced pruritus after cesarean delivery." | 9.10 | Nalbuphine versus ondansetron for prevention of intrathecal morphine-induced pruritus after cesarean delivery. ( Charuluxananan, S; Kyokong, O; Narasethakamol, A; Promlok, P; Somboonviboon, W, 2003) |
| "To assess the safety and efficacy of ondansetron for prevention of pruritus, nausea and vomiting after cesarean delivery with intrathecal sufentanil-morphine." | 9.10 | Prophylactic ondansetron is effective in the treatment of nausea and vomiting but not on pruritus after cesarean delivery with intrathecal sufentanil-morphine. ( Chalhoub, V; Haddad, F; Hayek, G; Madi-Jebara, S; Yazigi, A, 2002) |
| " Diazepam and benzodiazepines have been widely studied in pregnancy but the results are contradictory." | 9.09 | Evaluation of treatment of hyperemesis gravidarum using parenteral fluid with or without diazepam. A randomized study. ( De Leo, V; Ditto, A; la Marca, A; Morgante, G, 1999) |
| "Ondansetron prophylaxis significantly decreases the incidence of pruritus, a common side effect of intrathecal morphine used to treat postcesarean delivery pain." | 9.09 | Prophylactic intravenous ondansetron reduces the incidence of intrathecal morphine-induced pruritus in patients undergoing cesarean delivery. ( Chan, WH; Chen, LK; Chen, YP; Lin, CJ; Lin, CS; Sun, WZ; Tsai, SK; Wang, MJ; Yeh, HM, 2000) |
| "We attempted to determine whether the antiemetic ondansetron would be more effective than promethazine in treating hyperemesis gravidarum." | 9.08 | A pilot study of intravenous ondansetron for hyperemesis gravidarum. ( Johnson, CA; Martin, RW; Morrison, JC; Roach, H; Stewart, DK; Sullivan, CA, 1996) |
| "Ondansetron is increasingly used off label to treat nausea and vomiting during pregnancy." | 9.05 | Risk of malformation after ondansetron in pregnancy: An updated systematic review and meta-analysis. ( Berard, A; Cottin, J; Cucherat, M; Grenet, G; Picot, C; Ripoche, E, 2020) |
| "To investigate whether ondansetron use during pregnancy is associated with increased rates of major or subgroups of malformations." | 9.01 | Use of ondansetron during pregnancy and the risk of major congenital malformations: A systematic review and meta-analysis. ( Erol-Coskun, H; Kaplan, YC; Kennedy, D; Keskin-Arslan, E; Richardson, JL, 2019) |
| "Ondansetron, not approved for use in pregnancy, is increasingly being prescribed for nausea and vomiting in pregnancy and hyperemesis gravidarum." | 8.98 | Ondansetron in Pregnancy and the Risk of Congenital Malformations: A Systematic Review. ( Campbell, S; Chari, R; Lavecchia, M; Ross, S, 2018) |
| "To examine the risk of birth defects in children born to women who used ondansetron early in pregnancy for nausea and vomiting of pregnancy or hyperemesis gravidarum." | 8.93 | Ondansetron Use in Pregnancy and Birth Defects: A Systematic Review. ( Carstairs, SD, 2016) |
| "To examine the medical evidence regarding the clinical efficacy and cost-effectiveness of the application of continuous subcutaneous metoclopramide and ondansetron to treat nausea and vomiting during pregnancy." | 8.88 | Reviewing the evidence for using continuous subcutaneous metoclopramide and ondansetron to treat nausea & vomiting during pregnancy. ( Kirkbride, MS; Reichmann, JP, 2012) |
| "Ondansetron is a widely administered medication for nausea and vomiting of pregnancy." | 8.31 | Ondansetron Use During Pregnancy: Birth Defects and Obstetric Outcomes. ( Azab, AN; Betesh-Abay, B; Hadar, E; Masarwe, S; Peleg, N; Shvartsur, R, 2023) |
| "The objective of this study was to describe ondansetron drug utilization patterns during pregnancy to treat nausea and vomiting in pregnancy (NVP)." | 8.12 | Ondansetron use in nausea and vomiting during pregnancy: A descriptive analysis of prescription patterns and patient characteristics in UK general practice. ( Candore, G; Flynn, R; Kurz, X; Nordeng, H; Pinheiro, L; Quinten, C; Slattery, J, 2022) |
| "Although there is no recommendation in France relating to the treatment of nausea and vomiting of pregnancy, there are some in other countries, where ondansetron, widely used, appears to be an effective second-line treatment option behind doxylamine/vitamin B6 association and metoclopramide." | 8.02 | [Nausea and vomiting in pregnancy: A place for ondansetron?] ( Coulm, B, 2021) |
| "Ondansetron is commonly used to treat nausea and vomiting in pregnancy despite inconclusive evidence of its safety." | 8.02 | Ondansetron use in early pregnancy and the risk of miscarriage. ( Boggess, K; Engel, SM; Jonsson Funk, M; Lund, JL; Stürmer, T; Suarez, EA, 2021) |
| "Our results do not suggest that ondansetron increases the risk of preterm birth or gestational hypertensive disorders." | 8.02 | Ondansetron use in early pregnancy and the risk of late pregnancy outcomes. ( Boggess, K; Engel, SM; Funk, MJ; Lund, JL; Stürmer, T; Suarez, EA, 2021) |
| "The objective of the study was to evaluate the rate of major congenital anomalies after first trimester exposure to ondansetron for nausea and vomiting of pregnancy (NVP)." | 8.02 | Pregnancy outcome following in-utero exposure to ondansetron: A prospective comparative observational study. ( Arnon, J; Diav-Citrin, O; Sakran, R; Shechtman, S, 2021) |
| "Ondansetron is an effective antiemetic that is being widely used as a second-line treatment option for severe nausea and vomiting of pregnancy in accordance with clinical guidelines." | 8.02 | Ondansetron in pregnancy revisited: Assessment and pregnancy labelling by the European Medicines Agency (EMA) & Pharmacovigilance Risk Assessment Committee (PRAC). ( Cassina, M; Damkier, P; Diav-Citrin, O; Kaplan, YC; Shechtman, S; Weber-Schoendorfer, C, 2021) |
| "Literature is divided regarding the risk of neonatal ventricular septal defect (VSD) associated with first trimester ondansetron use in pregnancy." | 7.96 | Ondansetron use in the first trimester of pregnancy and the risk of neonatal ventricular septal defect. ( Bodnar, LM; Caritis, SN; Garrard, W; Lemon, LS; Marroquin, OC; Platt, RW; Venkataramanan, R, 2020) |
| " The rash started 2 days after the patient had started taking ondansetron 8 mg for alleviation of moderate-to-severe nausea and vomiting of pregnancy." | 7.88 | Pityriasis rosea-like eruption associated with ondansetron use in pregnancy. ( Alame, MM; Chamsy, DJ; Zaraket, H, 2018) |
| "To use data from two large studies of birth defects to describe time trends in ondansetron use for the treatment of first-trimester nausea and vomiting of pregnancy and to investigate associations, either previously reported or undescribed, between first-trimester ondansetron use and major birth defects." | 7.88 | Ondansetron for Treatment of Nausea and Vomiting of Pregnancy and the Risk of Specific Birth Defects. ( Anderka, M; Mitchell, AA; Parker, SE; Van Bennekom, C, 2018) |
| "This is an analysis of fetal outcome in pregnancies exposed to ondansetron to treat Hyperemesis Gravidarum (HG)." | 7.83 | Ondansetron in pregnancy and risk of adverse fetal outcomes in the United States. ( Fejzo, MS; MacGibbon, KW; Mullin, PM, 2016) |
| "Two cohort studies, including more than 2500 pregnant women exposed to ondansetron in early pregnancy, have raised concerns over an increased risk of congenital heart defects." | 7.83 | Ondansetron and pregnancy: possible congenital heart defects. ( , 2016) |
| "We describe a case of intestinal obstruction in a pregnant woman with severe nausea and vomiting of pregnancy treated with ondansetron, which is known to slow gut motility." | 7.80 | Intestinal obstruction in pregnancy by ondansetron. ( Berkovitch, M; Cohen, R; Dil, DN; Dinavitser, N; Koren, G; Shlomo, M, 2014) |
| "Ondansetron is frequently used to treat nausea and vomiting during pregnancy, but the safety of this drug for the fetus has not been well studied." | 7.79 | Ondansetron in pregnancy and risk of adverse fetal outcomes. ( Hviid, A; Pasternak, B; Svanström, H, 2013) |
| "Our study did not detect any adverse outcomes from the use of ondansetron in pregnancy but could not conclude that ondansetron is safe to use in pregnancy." | 7.79 | Off-label use of ondansetron in pregnancy in Western Australia. ( Bower, C; Colvin, L; Gill, AW; Slack-Smith, L; Stanley, FJ, 2013) |
| "This is a descriptive retrospective case series of 14 pregnant women treated with ondansetron for hyperemesis gravidarum (HG) at CHU Sainte-Justine, from January 2002 to October 2011." | 7.78 | Ondansetron use during pregnancy: a case series. ( Bussières, JF; Ferreira, E; Gillet, M; Lelièvre, J, 2012) |
| "While I usually prescribe doxylamine-pyridoxine for morning sickness, some of my patients with severe nausea and vomiting of pregnancy (NVP) receive ondansetron in hospital." | 7.78 | Motherisk update. Is ondansetron safe for use during pregnancy? ( Koren, G, 2012) |
| "Ondansetron (Zofran) is a drug used for the treatment of nausea and vomiting caused by cancer chemotherapy." | 7.72 | The safety of ondansetron for nausea and vomiting of pregnancy: a prospective comparative study. ( Einarson, A; Kennedy, D; Koren, G; Maltepe, C; Navioz, Y; Tan, MP, 2004) |
| "Ondansetron is a 5-HT3 receptor antagonist which is generally used for the prophylactic management of nausea and vomiting; however, studies have found that ondansetron might decrease the incidence of PDPH." | 6.80 | Effect of ondansetron on post-dural puncture headache (PDPH) in parturients undergoing cesarean section: a double-blind randomized placebo-controlled study. ( Fattahi, Z; Hadavi, SM; Sahmeddini, MA, 2015) |
| "This study's purpose was to determine if ondansetron can prevent pruritus after administration of intrathecal morphine in children, as has been demonstrated in adults." | 5.51 | Intravenous ondansetron reduced nausea but not pruritus following intrathecal morphine in children: Interim results of a randomized, double-blinded, placebo-control trial. ( Hong, RA; Leis, A; Li, Y; Malviya, S; Park, JM; Putnam, EM, 2022) |
| "Maternal hypotension is common after spinal anesthesia for cesarean delivery." | 5.43 | Ephedrine versus ondansetron in the prevention of hypotension during cesarean delivery: a randomized, double-blind, placebo-controlled trial. ( Nivatpumin, P; Thamvittayakul, V, 2016) |
| " There are numerous limitations in the current literature on ondansetron safety including exposure to the medication is not limited to sensitive windows of organogenesis, there is a lack of information on dosing and compliance, self-reports of exposure are commonly used, an inadequate accounting exists for other factors that may explain the relationship between ondansetron exposure and the adverse outcome, and there exists a lack of biologic plausibility by which ondansetron might cause harm." | 5.43 | Ondansetron Use in Pregnancy. ( Bodnar, LM; Caritis, SN; Siminerio, LL; Venkataramanan, R, 2016) |
| " The EMPOWER (EMesis in Pregnancy – Ondansetron With mEtoClopRamide) trial aimed to compare the clinical effectiveness and cost-effectiveness of two anti-sickness drugs [metoclopramide (metoclopramide hydrochloride, Actavis UK Ltd, Barnstable, UK; IV Ratiopharm GmbH, Ulm, Germany) and ondansetron (ondansetron hydrochloride dehydrate, Wockhardt UK Ltd, Wrexham, UK; IV Hameln Pharma plus GmbH, Hameln)] for the treatment of nausea and vomiting in pregnancy." | 5.41 | Ondansetron and metoclopramide as second-line antiemetics in women with nausea and vomiting in pregnancy: the EMPOWER pilot factorial RCT. ( Campbell, I; Fernandez-Garcia, C; Goudie, N; Graham, R; Howel, D; Lie, M; McColl, E; McParlin, C; Mossop, H; Nadeem, A; Nelson-Piercy, C; O'Hara, ME; Phillipson, J; Robson, S; Shehmar, M; Simpson, N; Steel, A; Ternent, L; Tuffnell, D; Williams, R, 2021) |
| "Although ondansetron was considered to prevent post-anesthesia shivering during cesarean section, its efficiency remained controversial." | 5.41 | A meta-analysis of randomized controlled trials: efficiency and safety of ondansetron in preventing post-anesthesia shivering during cesarean section. ( Cao, F; Chen, C; Liu, J; Zhang, J; Zhang, L; Zheng, G, 2023) |
| "Based on the results of this study, ondansetron had a significant effect on the alleviation of postoperative nausea and vomiting, as compared to dexamethasone in C-section surgical candidates." | 5.41 | Comparison of the Effects of Dexamethasone and Ondansetron on the Reduction of Postoperative Nausea and Vomiting following Cesarean Section under Spinal Anesthesia. ( Birjandi, M; Karimi, A; Nejadi, JR; Ronasi, N; Shamseh, M, 2021) |
| "This study aimed to determine whether gabapentin is more effective than standard-of-care therapy for treating hyperemesis gravidarum." | 5.41 | Effect of gabapentin on hyperemesis gravidarum: a double-blind, randomized controlled trial. ( Guttuso, T; Messing, S; Mullin, P; Saha, S; Shepherd, R; Strittmatter, C; Thornburg, LL; Tu, X, 2021) |
| "The objective of this randomised, double blinded clinical trial was to evaluate the efficacy of prophylactic administration of 4 mg ondansetron as monotherapy versus combination therapy of 4 mg ondansetron plus 8 mg dexamethasone for the prevention of intrathecal morphine-associated pruritus in caesarean section within 24 h." | 5.41 | Ondansetron versus ondansetron with dexamethasone to prevent intrathecal-morphine pruritus for caesarean patients: randomised double-blind trial. ( Ankouni, T; El Hassan, J; El Khatib, R; Itani, SE; Kanawati, S; Naja, Z; Rajab, O, 2021) |
| "Ondansetron has been shown to reduce the incidence of hypotension and vasopressor requirement during spinal anesthesia for obstetric and nonobstetric surgery." | 5.34 | A Prospective, Randomized, Double-Blinded Study of the Effect of Intravenous Ondansetron on the Effective Dose in 50% of Subjects of Prophylactic Phenylephrine Infusions for Preventing Spinal Anesthesia-Induced Hypotension During Cesarean Delivery. ( Chang, X; Chen, X; Ngan Kee, WD; Shen, H; Wei, C; Xiao, F; Xue, L; Zhang, Y, 2020) |
| " One hundred and eighty pregnant women referred to secondary care for hyperemesis gravidarum will be randomly allocated to 14-day treatment with either mirtazapine, ondansetron or placebo." | 5.34 | Validating the effect of Ondansetron and Mirtazapine In Treating hyperemesis gravidarum (VOMIT): protocol for a randomised placebo-controlled trial. ( Andersen, JT; Futtrup, TB; Jensen, AK; Løkkegaard, ECL; Ostenfeld, A; Pedersen, LH; Petersen, TS; Westergaard, HB, 2020) |
| "There was controversy about ondansetron can reduce the incidence of spinal-induced hypotension and decrease the consumption of vasopressor in cesarean delivery with spinal anesthesia." | 5.34 | Does an Earlier or Late Intravenous Injection of Ondansetron Affect the Dose of Phenylephrine Needed to Prevent Spinal-Anesthesia Induced Hypotension in Cesarean Sections? ( Liu, L; Qian, J; Xiao, F; Zheng, X, 2020) |
| "Hyperemesis gravidarum is a disabling condition." | 5.31 | Treatment of intractable hyperemesis gravidarum by ondansetron. ( Cheung, CW; Lau, TK; Siu, SS; Yip, SK, 2002) |
| "Ondansetron is a 5-hydroxytryptamine receptor antagonist which is known to be a highly effective anti-emetic drug for chemotherapy-associated nausea and vomiting and for postoperative nausea." | 5.29 | Treatment of hyperemesis gravidarum with the 5-HT3 antagonist ondansetron (Zofran). ( Johnstone, MJ; Tincello, DG, 1996) |
| " No significant difference was found in the incidence of hypotension in the saline and ondansetron groups (p = 0." | 5.27 | Does prophylactic ondansetron reduce norepinephrine consumption in patients undergoing cesarean section with spinal anesthesia? ( Biricik, E; Büyükkurt, S; Karacaer, F; Ünal, İ; Ünlügenç, H, 2018) |
| "The weight-based dosing of ondansetron to reduce hypotension has never been investigated." | 5.27 | Minimal effective weight-based dosing of ondansetron to reduce hypotension in cesarean section under spinal anesthesia: a randomized controlled superiority trial. ( Dilokrattanaphijit, N; Karnjanawanichkul, O; Kunapaisal, T; Leeratiwong, J; Oofuvong, M, 2018) |
| "To evaluate the effect of prophylactic ondansetron on spinal anesthesia-induced hypotension and bradycardia among patients undergoing elective cesarean deliveries." | 5.22 | Randomized controlled trial comparing ondansetron and placebo for the reduction of spinal anesthesia-induced hypotension during elective cesarean delivery in Egypt. ( El Khouly, NI; Meligy, AM, 2016) |
| "Ondansetron is the drug of choice to prevent nausea in women undergoing cesarean surgery and can be used to prevent neonatal abstinence syndrome (NAS)." | 5.20 | Ondansetron pharmacokinetics in pregnant women and neonates: towards a new treatment for neonatal abstinence syndrome. ( Carvalho, B; Clavijo, C; Drover, DR; Elkomy, MH; Galinkin, JL; Peltz, G; Sultan, P; Wu, M, 2015) |
| "Prophylactic administration of ondansetron to parturients receiving intrathecal morphine for post-operative analgesia provides a significant reduction of intrathecal morphine-induced pruritus and nausea and vomiting." | 5.20 | Prophylactic administration of ondansetron in prevention of intrathecal morphine-induced pruritus and post-operative nausea and vomiting in patients undergoing caesarean section. ( Dongol, Y; Gurung, BS; Koju, RB, 2015) |
| "verification of a hypothesis assuming that 5-HT3 receptor blockade by intravenous administration of ondansetron reduces the incidence of hypotension and bradycardia in patients undergoing spinal anaesthesia for Caesarean section." | 5.20 | The influence of intravenous ondansetron on maternal blood haemodynamics after spinal anaesthesia for caesarean section: a double-blind, placebo-controlled study. ( Majdyło, K; Marciniak, A; Owczuk, R; Preis, K; Wujtewicz, M, 2015) |
| "Maternal hypotension and nausea were significantly lower in ondansetron-treated patients versus placebo (p = 0." | 5.19 | Ondansetron preloading with crystalloid infusion reduces maternal hypotension during cesarean delivery. ( Shen, MK; Wang, M; Wang, Q; Yu, JJ; Yu, YY; Zhuo, L, 2014) |
| "To compare ondansetron with metoclopramide in the treatment of hyperemesis gravidarum." | 5.19 | Ondansetron compared with metoclopramide for hyperemesis gravidarum: a randomized controlled trial. ( Abas, MN; Azmi, N; Omar, SZ; Tan, PC, 2014) |
| "Healthy paturients undergoing cesarean delivery with intrathecal morphine 250μg and fentanyl 25μg were randomized to receive: prophylaxis (ondansetron 8mg at cord clamping, normal saline 4mL for treatment of pruritus in the post-anaesthesia care unit); treatment (normal saline 4mL at cord clamping, ondansetron 8mg as required in the post-anesthesia care unit) or control (normal saline 4mL in both)." | 5.19 | Prevention versus treatment of intrathecal morphine-induced pruritus with ondansetron. ( Hess, P; Kung, AT; Li, Y; Pratt, S; Vasudevan, A; Yang, X, 2014) |
| "Our investigation showed ondansetron to be superior to the combination of pyridoxine and doxylamine in the treatment of nausea and emesis in pregnancy." | 5.19 | Ondansetron compared with doxylamine and pyridoxine for treatment of nausea in pregnancy: a randomized controlled trial. ( Capp, SM; Carstairs, SD; Oliveira, LG; Riffenburgh, RH; You, WB, 2014) |
| " This prospective, randomized, double blind study was carried out to compare the effectiveness of a combination of dexamethasone and ondansetron with dexamethasone alone for prevention of postoperative nausea and vomiting (PONV) following intrathecal morphine injection for caesarean section." | 5.19 | Dexamethasone versus a combination of dexamethasone and ondansetron as prophylactic antiemetic in patients receiving intrathecal morphine for caesarean section. ( Imeh, A; Olaniyi, O; Omotola, O; Simeon, O, 2014) |
| "To estimate whether the addition of metoclopramide or its combination with ondansetron to a prophylactic phenylephrine infusion provides improved intraoperative nausea and vomiting prophylaxis compared with phenylephrine infusion alone." | 5.17 | Antiemetics added to phenylephrine infusion during cesarean delivery: a randomized controlled trial. ( Allen, TK; George, RB; Habib, AS; Ituk, US; McKeen, DM; Megalla, SA; White, WD, 2013) |
| "Ondansetron 4 mg, given intravenously 5 min before subarachnoid block reduced hypotension and vasopressor use in parturients undergoing elective caesarean section." | 5.16 | Reduction in spinal-induced hypotension with ondansetron in parturients undergoing caesarean section: a double-blind randomised, placebo-controlled study. ( Goswami, A; Hazra, A; Sahoo, T; SenDasgupta, C, 2012) |
| "Ondansetron is effective for the treatment of intrathecal morphine-induced pruritus." | 5.14 | A randomized controlled trial of pentazocine versus ondansetron for the treatment of intrathecal morphine-induced pruritus in patients undergoing cesarean delivery. ( Charuluxananan, S; Patumanond, J; Punjasawadwong, Y; Sriprajittichai, P; Tamdee, D; Tawichasri, C, 2009) |
| " reduces the severity of pruritus and the use of rescue anti-pruritic medication, and improves satisfaction but does not reduce the overall incidence of pruritus in women who have received subarachnoid morphine 150 microg compared to ondansetron 8 mg i." | 5.14 | Reduction of severity of pruritus after elective caesarean section under spinal anaesthesia with subarachnoid morphine: a randomised comparison of prophylactic granisetron and ondansetron. ( Carey, M; Choroszczak, P; Immani, S; Ojo, R; Tan, T, 2010) |
| "Ondansetron is as effective as diphenhydramine in relieving pruritus caused by SA morphine in patients undergoing a cesarean delivery." | 5.14 | Ondansetron is as effective as diphenhydramine for treatment of morphine-induced pruritus after cesarean delivery. ( Adham, AM; Aouad, MT; Dagher, CM; Saasouh, WA; Siddik-Sayyid, SM; Yazbeck-Karam, VG; Zahreddine, BW, 2010) |
| "To study the association between ondansetron exposure during pregnancy and the risks of spontaneous abortion, stillbirth, and major congenital malformations." | 5.12 | Comparison of Pregnancy Outcomes of Patients Treated With Ondansetron vs Alternative Antiemetic Medications in a Multinational, Population-Based Cohort. ( Dahl, M; Dormuth, CR; Filion, KB; Fisher, A; Lu, X; Ma, Z; Moriello, C; Paterson, JM; Platt, RW; Raymond, CB; Reynier, P; Suissa, S; Winquist, B; Wu, F; Zhang, J, 2021) |
| "Neither ondansetron nor tropisetron prevent itching caused by intrathecal morphine with fentanyl." | 5.12 | Ondansetron and tropisetron do not prevent intraspinal morphine- and fentanyl-induced pruritus in elective cesarean delivery. ( Halonen, PM; Kainu, JP; Korttila, KT; Sarvela, PJ; Soikkeli, AI, 2006) |
| "We compared the efficacy of granisetron and ondansetron for the prevention of subarachnoid morphine-induced pruritus after cesarean delivery." | 5.12 | Does ondansetron or granisetron prevent subarachnoid morphine-induced pruritus after cesarean delivery? ( Aouad, MT; Azar, MS; Baraka, AS; Hakki, MA; Kaddoum, RN; Nasr, VG; Siddik-Sayyid, SM; Taha, SK; Yazbek, VG, 2007) |
| "In this randomized, double-blind study, we aimed to compare the effectiveness of lornoxicam and ondansetron for the prevention of intrathecal fentanyl-induced pruritus in patients undergoing cesarean section." | 5.12 | Lornoxicam and ondansetron for the prevention of intrathecal fentanyl-induced pruritus. ( Begec, Z; Erdil, FA; Ersoy, MO; Gedik, E; Gulhas, N; Sagir, O; Togal, T, 2007) |
| " The incidence of pruritus and nausea was significantly lower in the epidural ondansetron group than in the intravenous ondansetron group at 24 and 48 h postoperatively." | 5.12 | Epidural ondansetron is more effective to prevent postoperative pruritus and nausea than intravenous ondansetron in elective cesarean delivery. ( Han, DW; Hong, SW; Kim, KJ; Kwon, JY; Lee, JW, 2007) |
| "Fentanyl is commonly used for spinal analgesia during labour but it is associated with a high incidence of pruritus." | 5.11 | Intrathecal fentanyl-induced pruritus during labour: the effect of prophylactic ondansetron. ( Evans, SF; Paech, MJ; Wells, J, 2004) |
| "In this prospective, randomized, double-blinded study, we compared the prophylactic efficacy of nalbuphine and ondansetron for the prevention of intrathecal morphine-induced pruritus after cesarean delivery." | 5.10 | Nalbuphine versus ondansetron for prevention of intrathecal morphine-induced pruritus after cesarean delivery. ( Charuluxananan, S; Kyokong, O; Narasethakamol, A; Promlok, P; Somboonviboon, W, 2003) |
| "To assess the safety and efficacy of ondansetron for prevention of pruritus, nausea and vomiting after cesarean delivery with intrathecal sufentanil-morphine." | 5.10 | Prophylactic ondansetron is effective in the treatment of nausea and vomiting but not on pruritus after cesarean delivery with intrathecal sufentanil-morphine. ( Chalhoub, V; Haddad, F; Hayek, G; Madi-Jebara, S; Yazigi, A, 2002) |
| " Diazepam and benzodiazepines have been widely studied in pregnancy but the results are contradictory." | 5.09 | Evaluation of treatment of hyperemesis gravidarum using parenteral fluid with or without diazepam. A randomized study. ( De Leo, V; Ditto, A; la Marca, A; Morgante, G, 1999) |
| "Ondansetron prophylaxis significantly decreases the incidence of pruritus, a common side effect of intrathecal morphine used to treat postcesarean delivery pain." | 5.09 | Prophylactic intravenous ondansetron reduces the incidence of intrathecal morphine-induced pruritus in patients undergoing cesarean delivery. ( Chan, WH; Chen, LK; Chen, YP; Lin, CJ; Lin, CS; Sun, WZ; Tsai, SK; Wang, MJ; Yeh, HM, 2000) |
| "The efficacy of ondansetron and droperidol were evaluated for prophylactic treatment of nausea and vomiting in cesarean section patients under epidural anesthesia." | 5.08 | Intraoperative antiemetic efficacy of prophylactic ondansetron versus droperidol for cesarean section patients under epidural anesthesia. ( Moore, CH; Pan, PH, 1996) |
| "We attempted to determine whether the antiemetic ondansetron would be more effective than promethazine in treating hyperemesis gravidarum." | 5.08 | A pilot study of intravenous ondansetron for hyperemesis gravidarum. ( Johnson, CA; Martin, RW; Morrison, JC; Roach, H; Stewart, DK; Sullivan, CA, 1996) |
| "Ondansetron is increasingly used off label to treat nausea and vomiting during pregnancy." | 5.05 | Risk of malformation after ondansetron in pregnancy: An updated systematic review and meta-analysis. ( Berard, A; Cottin, J; Cucherat, M; Grenet, G; Picot, C; Ripoche, E, 2020) |
| "While interventions such as crystalloids, colloids, ephedrine, phenylephrine, ondansetron, or lower leg compression can reduce the incidence of hypotension, none have been shown to eliminate the need to treat maternal hypotension in some women." | 5.05 | Techniques for preventing hypotension during spinal anaesthesia for caesarean section. ( Chemali, M; Chooi, C; Cox, JJ; Cyna, AM; Emmett, RS; Lumb, RS; Middleton, P; Simmons, SW, 2020) |
| "To investigate whether ondansetron use during pregnancy is associated with increased rates of major or subgroups of malformations." | 5.01 | Use of ondansetron during pregnancy and the risk of major congenital malformations: A systematic review and meta-analysis. ( Erol-Coskun, H; Kaplan, YC; Kennedy, D; Keskin-Arslan, E; Richardson, JL, 2019) |
| "Ondansetron, not approved for use in pregnancy, is increasingly being prescribed for nausea and vomiting in pregnancy and hyperemesis gravidarum." | 4.98 | Ondansetron in Pregnancy and the Risk of Congenital Malformations: A Systematic Review. ( Campbell, S; Chari, R; Lavecchia, M; Ross, S, 2018) |
| " (June issue of Reproductive Toxicology) on the relationship of ondansetron exposure to pregnancy outcome and birth defects." | 4.95 | Publishing negative findings and the challenge of avoiding type II errors in studies of suspect teratogens: Example of a recent ondansetron publication. ( Edlavitch, SA, 2017) |
| "To examine the risk of birth defects in children born to women who used ondansetron early in pregnancy for nausea and vomiting of pregnancy or hyperemesis gravidarum." | 4.93 | Ondansetron Use in Pregnancy and Birth Defects: A Systematic Review. ( Carstairs, SD, 2016) |
| "For mild symptoms of nausea and emesis of pregnancy, ginger, pyridoxine, antihistamines, and metoclopramide were associated with greater benefit than placebo." | 4.93 | Treatments for Hyperemesis Gravidarum and Nausea and Vomiting in Pregnancy: A Systematic Review. ( Beyer, F; Bradley, J; Bryant, A; McParlin, C; Moloney, E; Muirhead, CR; Nelson-Piercy, C; Newbury-Birch, D; Norman, J; O'Donnell, A; Robson, SC; Shaw, C; Simpson, E; Swallow, B; Vale, L; Yates, L, 2016) |
| "To examine the medical evidence regarding the clinical efficacy and cost-effectiveness of the application of continuous subcutaneous metoclopramide and ondansetron to treat nausea and vomiting during pregnancy." | 4.88 | Reviewing the evidence for using continuous subcutaneous metoclopramide and ondansetron to treat nausea & vomiting during pregnancy. ( Kirkbride, MS; Reichmann, JP, 2012) |
| "Ondansetron is a 5HT3 receptor antagonist, used to mitigate the effects of nausea and vomiting after chemotherapy or surgery." | 4.31 | Embryo-fetal safety evaluation of ondansetron in rats. ( Arena, AC; da Silva Moreira, S; de Matos Manoel, B; Jorge, BC; Perdão, CB; Reis, ACC; Stein, J, 2023) |
| "Ondansetron is a widely administered medication for nausea and vomiting of pregnancy." | 4.31 | Ondansetron Use During Pregnancy: Birth Defects and Obstetric Outcomes. ( Azab, AN; Betesh-Abay, B; Hadar, E; Masarwe, S; Peleg, N; Shvartsur, R, 2023) |
| "Ondansetron is a highly effective antiemetic for the treatment of nausea and vomiting." | 4.12 | A pharmacogenomic investigation of the cardiac safety profile of ondansetron in children and pregnant women. ( Berger, H; Brodie, SM; Brown, J; Carleton, BC; Chaudhry, S; Drögemöller, BI; Groeneweg, GSS; Higginson, M; Israels, S; Ito, S; Jong, G'; Magee, LA; Miao, F; Rassekh, SR; Ross, CJD; Sanatani, S; Shaw, K; Staub, M; Trueman, J; West, N; Whyte, SD; Wright, GEB, 2022) |
| "The objective of this study was to describe ondansetron drug utilization patterns during pregnancy to treat nausea and vomiting in pregnancy (NVP)." | 4.12 | Ondansetron use in nausea and vomiting during pregnancy: A descriptive analysis of prescription patterns and patient characteristics in UK general practice. ( Candore, G; Flynn, R; Kurz, X; Nordeng, H; Pinheiro, L; Quinten, C; Slattery, J, 2022) |
| "Although there is no recommendation in France relating to the treatment of nausea and vomiting of pregnancy, there are some in other countries, where ondansetron, widely used, appears to be an effective second-line treatment option behind doxylamine/vitamin B6 association and metoclopramide." | 4.02 | [Nausea and vomiting in pregnancy: A place for ondansetron?] ( Coulm, B, 2021) |
| "Ondansetron is commonly used to treat nausea and vomiting in pregnancy despite inconclusive evidence of its safety." | 4.02 | Ondansetron use in early pregnancy and the risk of miscarriage. ( Boggess, K; Engel, SM; Jonsson Funk, M; Lund, JL; Stürmer, T; Suarez, EA, 2021) |
| "Our results do not suggest that ondansetron increases the risk of preterm birth or gestational hypertensive disorders." | 4.02 | Ondansetron use in early pregnancy and the risk of late pregnancy outcomes. ( Boggess, K; Engel, SM; Funk, MJ; Lund, JL; Stürmer, T; Suarez, EA, 2021) |
| "The objective of the study was to evaluate the rate of major congenital anomalies after first trimester exposure to ondansetron for nausea and vomiting of pregnancy (NVP)." | 4.02 | Pregnancy outcome following in-utero exposure to ondansetron: A prospective comparative observational study. ( Arnon, J; Diav-Citrin, O; Sakran, R; Shechtman, S, 2021) |
| "Ondansetron is an effective antiemetic that is being widely used as a second-line treatment option for severe nausea and vomiting of pregnancy in accordance with clinical guidelines." | 4.02 | Ondansetron in pregnancy revisited: Assessment and pregnancy labelling by the European Medicines Agency (EMA) & Pharmacovigilance Risk Assessment Committee (PRAC). ( Cassina, M; Damkier, P; Diav-Citrin, O; Kaplan, YC; Shechtman, S; Weber-Schoendorfer, C, 2021) |
| "Literature is divided regarding the risk of neonatal ventricular septal defect (VSD) associated with first trimester ondansetron use in pregnancy." | 3.96 | Ondansetron use in the first trimester of pregnancy and the risk of neonatal ventricular septal defect. ( Bodnar, LM; Caritis, SN; Garrard, W; Lemon, LS; Marroquin, OC; Platt, RW; Venkataramanan, R, 2020) |
| "Using the Quebec Pregnancy Cohort (1998-2015), first-trimester doxylamine-pyridoxine, metoclopramide, and ondansetron exposures were assessed for their association with MCM." | 3.91 | New evidence for concern over the risk of birth defects from medications for nausea and vomitting of pregnancy. ( Bérard, A; Bernatsky, S; Gorgui, J; Sheehy, O; Soares de Moura, C; Zhao, JP, 2019) |
| " The rash started 2 days after the patient had started taking ondansetron 8 mg for alleviation of moderate-to-severe nausea and vomiting of pregnancy." | 3.88 | Pityriasis rosea-like eruption associated with ondansetron use in pregnancy. ( Alame, MM; Chamsy, DJ; Zaraket, H, 2018) |
| "To use data from two large studies of birth defects to describe time trends in ondansetron use for the treatment of first-trimester nausea and vomiting of pregnancy and to investigate associations, either previously reported or undescribed, between first-trimester ondansetron use and major birth defects." | 3.88 | Ondansetron for Treatment of Nausea and Vomiting of Pregnancy and the Risk of Specific Birth Defects. ( Anderka, M; Mitchell, AA; Parker, SE; Van Bennekom, C, 2018) |
| "The potent hERG channel blocking drug ondansetron is used off-label for treatment of nausea and vomiting in early pregnancy." | 3.88 | Ondansetron and teratogenicity in rats: Evidence for a mechanism mediated via embryonic hERG blockade. ( Danielsson, B; Ritchie, HE; Webster, WS, 2018) |
| "Evidence for the fetal safety of ondansetron, a 5-HT3 receptor antagonist that is commonly prescribed for nausea and vomiting during pregnancy, is limited and conflicting." | 3.88 | Association of Maternal First-Trimester Ondansetron Use With Cardiac Malformations and Oral Clefts in Offspring. ( Bateman, BT; Desai, RJ; Gray, KJ; Hernández-Díaz, S; Huybrechts, KF; Mogun, H; Patorno, E; Straub, L; Zhu, Y, 2018) |
| "To examine ondansetron use in pregnancy in the context of other antiemetic use among a large insured United States population of women delivering live births." | 3.85 | Antiemetic use among pregnant women in the United States: the escalating use of ondansetron. ( Andrade, SE; Bird, ST; Greene, P; Haffenreffer, K; Reichman, ME; Sahin, L; Tassinari, MS; Taylor, LG; Toh, S, 2017) |
| "This is an analysis of fetal outcome in pregnancies exposed to ondansetron to treat Hyperemesis Gravidarum (HG)." | 3.83 | Ondansetron in pregnancy and risk of adverse fetal outcomes in the United States. ( Fejzo, MS; MacGibbon, KW; Mullin, PM, 2016) |
| "Two cohort studies, including more than 2500 pregnant women exposed to ondansetron in early pregnancy, have raised concerns over an increased risk of congenital heart defects." | 3.83 | Ondansetron and pregnancy: possible congenital heart defects. ( , 2016) |
| "The use of ondansetron in the ED for nausea and vomiting of pregnancy was associated with similar mean time from administration to disposition as other antiemetics." | 3.81 | Comparison of antiemetics for nausea and vomiting of pregnancy in an emergency department setting. ( Gray, R; Lopes, V; Matteson, KA; Mayhall, EA, 2015) |
| "The exposed group (n = 143) was comprised of children whose mothers received promethazine or ondansetron during pregnancy." | 3.80 | Antiemetic medications in pregnancy: a prospective investigation of obstetric and neurobehavioral outcomes. ( Dajani, NK; Eswaran, H; Larrimer, MB; Newport, DJ; Siegel, ER; Stowe, ZN, 2014) |
| "Ondansetron is frequently used to treat nausea and vomiting during pregnancy, but the safety of this drug for the fetus has not been well studied." | 3.79 | Ondansetron in pregnancy and risk of adverse fetal outcomes. ( Hviid, A; Pasternak, B; Svanström, H, 2013) |
| "Our study did not detect any adverse outcomes from the use of ondansetron in pregnancy but could not conclude that ondansetron is safe to use in pregnancy." | 3.79 | Off-label use of ondansetron in pregnancy in Western Australia. ( Bower, C; Colvin, L; Gill, AW; Slack-Smith, L; Stanley, FJ, 2013) |
| " For morning sickness, 89% of those replying give dietary advice frequently or always, and 70% prescribe metoclopramide frequently or always, whereas 59% advise pyridoxine and 10% prescribe doxylamine." | 3.79 | A survey of prescribing for the management of nausea and vomiting in pregnancy in Australasia. ( Raymond, SH, 2013) |
| "This is a descriptive retrospective case series of 14 pregnant women treated with ondansetron for hyperemesis gravidarum (HG) at CHU Sainte-Justine, from January 2002 to October 2011." | 3.78 | Ondansetron use during pregnancy: a case series. ( Bussières, JF; Ferreira, E; Gillet, M; Lelièvre, J, 2012) |
| "While I usually prescribe doxylamine-pyridoxine for morning sickness, some of my patients with severe nausea and vomiting of pregnancy (NVP) receive ondansetron in hospital." | 3.78 | Motherisk update. Is ondansetron safe for use during pregnancy? ( Koren, G, 2012) |
| " The experience with mitoxantrone (MIX) especially in the first trimenon is very limited, until now only one case of a pregnant woman with MS who was exposed to MIX in early pregnancy and delivered a growth restricted but healthy child was published." | 3.77 | A newborn with Pierre Robin sequence after preconceptional mitoxantrone exposure of a female with multiple sclerosis. ( Chan, A; Epplen, J; Gold, R; Hellwig, K; Schimrigk, S, 2011) |
| "We examined treatment outcomes in women with severe nausea and vomiting of pregnancy (NVP) receiving outpatient nursing support and either subcutaneous metoclopramide or subcutaneous ondansetron via a microinfusion pump." | 3.77 | Treatment of severe nausea and vomiting of pregnancy with subcutaneous medications. ( Desch, C; Fox, NS; Istwan, N; Klauser, CK; Palmer, B; Rebarber, A; Rhea, D; Saltzman, D, 2011) |
| "The role of peripheral 5-HT3 receptors in the nociceptive behavioral response and the effect of the 5-HT3 antagonist ondansetron on indices of acute and tonic pain were investigated in the formalin test in 25- and 90-day-old Wistar male rats." | 3.74 | [Antinociceptive properties of the 5-HT3 receptor antagonist in the model of inflammatory pain in rats of different age with prenatal deficit of serotonine and under stress]. ( Butkevich, IP; Makukhina, GV; Mikhaĭlenko, VA, 2007) |
| "Ondansetron (Zofran) is a drug used for the treatment of nausea and vomiting caused by cancer chemotherapy." | 3.72 | The safety of ondansetron for nausea and vomiting of pregnancy: a prospective comparative study. ( Einarson, A; Kennedy, D; Koren, G; Maltepe, C; Navioz, Y; Tan, MP, 2004) |
| "The esketamine (S) group was given esketamine +sufentanil + ondansetron, and the control (C) group was given sufentanil +ondansetron." | 3.30 | Low-dose esketamine with sufentanil for postcesarean analgesia in women with gestational diabetes mellitus: a prospective, randomized, double-blind study. ( Chen, L; Chen, Q; Han, T; Huang, J; Li, A; Li, Z; Peng, Z; Xu, W; Zhang, J, 2023) |
| "Ondansetron is a 5-HT3 receptor antagonist which is generally used for the prophylactic management of nausea and vomiting; however, studies have found that ondansetron might decrease the incidence of PDPH." | 2.80 | Effect of ondansetron on post-dural puncture headache (PDPH) in parturients undergoing cesarean section: a double-blind randomized placebo-controlled study. ( Fattahi, Z; Hadavi, SM; Sahmeddini, MA, 2015) |
| "Ondansetron was effective in reducing the incidence of nausea and vomiting in patients receiving intrathecal morphine for Caesarean section." | 2.72 | Ondansetron or droperidol for prophylaxis of nausea and vomiting after intrathecal morphine. ( Celich, MF; Peixoto Filho, AJ; Peixoto, AJ; Zardo, L, 2006) |
| "Cerebellar dysfunction was quantified before and after treatment using the International Cooperative Ataxia Rating Scale (ICARS)." | 2.71 | Effects of the oral form of ondansetron on cerebellar dysfunction. A multi-center double-blind study. ( Bier, JC; Dethy, S; Hildebrand, J; Jacquy, J; Manto, M; Martin, JJ; Seeldrayers, P, 2003) |
| "The frequency of intraoperative and postoperative vomiting were similar between Group O and Group M, but significantly higher in Group P (p < 0." | 2.70 | Comparing the efficacy of prophylactic metoclopramide, ondansetron, and placebo in cesarean section patients given epidural anesthesia. ( Moore, CH; Pan, PH, 2001) |
| "Ondansetron is a 5-HT₃ receptor antagonist that has been approved for the prevention of nausea and vomiting associated with cancer chemotherapy, radiotherapy, and surgery." | 2.66 | Major Congenital Malformation Risk After First Trimester Gestational Exposure to Oral or Intravenous Ondansetron. ( Andrade, C, 2020) |
| "Hyperemesis gravidarum is a severe form of nausea and vomiting in pregnancy affecting 0." | 2.53 | Interventions for treating hyperemesis gravidarum. ( Barton, SJ; Berghella, V; Boelig, RC; Edwards, SJ; Kelly, AJ; Saccone, G, 2016) |
| "Of note, co-existing gastroesophageal reflux disease (GERD), Helicobacter pylori infection, and psychosocial factors may have a negative impact on the management of NVP." | 2.50 | The outpatient management and special considerations of nausea and vomiting in pregnancy. ( Clark, SM; Dutta, E; Hankins, GD, 2014) |
| "Ondansetron is a 5HT3 receptor antagonist widely used to treat hyperemesis gravidarum, although its safety is still questionable." | 1.91 | Safety evaluation of ondansetron after gestational exposure on male reproductive parameters in rats. ( Aquino, AM; Arena, AC; Jorge, BC; Kassuya, CAL; Manoel, BM; Moreira, SDS; Reis, ACC; Scarano, WR; Stein, J; Valente, LC, 2023) |
| "Our results suggest that routine administration of ODS in a dosage of 8 mg does not effectively attenuate postspinal change in maternal blood pressure during CS in our setting." | 1.56 | 5-HT3 blockade does not attenuate postspinal blood pressure change in cesarean section: A case-control study. ( Heik-Guth, C; Hilbert, T; Klaschik, S; Neumann, C; Strizek, B; Velten, M; Wittmann, M, 2020) |
| "Physiologically based pharmacokinetic modeling is considered a valuable tool for predicting pharmacokinetic changes in pregnancy to subsequently guide in-vivo pharmacokinetic trials in pregnant women." | 1.48 | A Physiologically Based Pharmacokinetic Model for Pregnant Women to Predict the Pharmacokinetics of Drugs Metabolized Via Several Enzymatic Pathways. ( Coboeken, K; Dallmann, A; Eissing, T; Hempel, G; Ince, I, 2018) |
| "Nausea during pregnancy affects 80% of pregnant women and can severely affect women's functioning and quality of life." | 1.48 | Getting through the day: a pilot qualitative study of U.S. women's experiences making decisions about anti-nausea medication during pregnancy. ( Dublin, S; Figueroa Gray, M; Hsu, C; Kiel, L, 2018) |
| "Maternal hypotension is common after spinal anesthesia for cesarean delivery." | 1.43 | Ephedrine versus ondansetron in the prevention of hypotension during cesarean delivery: a randomized, double-blind, placebo-controlled trial. ( Nivatpumin, P; Thamvittayakul, V, 2016) |
| " There are numerous limitations in the current literature on ondansetron safety including exposure to the medication is not limited to sensitive windows of organogenesis, there is a lack of information on dosing and compliance, self-reports of exposure are commonly used, an inadequate accounting exists for other factors that may explain the relationship between ondansetron exposure and the adverse outcome, and there exists a lack of biologic plausibility by which ondansetron might cause harm." | 1.43 | Ondansetron Use in Pregnancy. ( Bodnar, LM; Caritis, SN; Siminerio, LL; Venkataramanan, R, 2016) |
| "Ondansetron is a substrate of cytochrome P450 (CYP) 3A4 (primary metabolic pathway), 2D6, and 1A2, all of which are altered during pregnancy." | 1.43 | Ondansetron Exposure Changes in a Pregnant Woman. ( Caritis, SN; Haas, DM; Hankins, GD; Hebert, MF; Lemon, LS; Venkataramanan, R; Zhang, H, 2016) |
| "A client could have weight loss, dehydration, nutritional deficiencies, metabolic deficiencies, difficulty with daily activities, psychosocial stress and depression." | 1.35 | A case study approach to Hyperemesis Gravidarum: home care implications. ( Jennings-Sanders, A, 2009) |
| "The effects of seizures were observed to a much larger extent in malformed than in normal brain tissue." | 1.33 | Determinants of drug brain uptake in a rat model of seizure-associated malformations of cortical development. ( Bassanini, S; Battaglia, G; Caccia, S; Chimenti, S; Gagliardi, B; Guiso, G; Marchi, N; Noé, F; Ravizza, T; Rizzi, M; Vezzani, A, 2006) |
| "Hyperemesis gravidarum is a disabling condition." | 1.31 | Treatment of intractable hyperemesis gravidarum by ondansetron. ( Cheung, CW; Lau, TK; Siu, SS; Yip, SK, 2002) |
| "Ondansetron is a 5-hydroxytryptamine receptor antagonist which is known to be a highly effective anti-emetic drug for chemotherapy-associated nausea and vomiting and for postoperative nausea." | 1.29 | Treatment of hyperemesis gravidarum with the 5-HT3 antagonist ondansetron (Zofran). ( Johnstone, MJ; Tincello, DG, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 13 (7.74) | 18.2507 |
| 2000's | 30 (17.86) | 29.6817 |
| 2010's | 88 (52.38) | 24.3611 |
| 2020's | 37 (22.02) | 2.80 |
| Authors | Studies |
|---|---|
| Coulm, B | 1 |
| Robson, S | 1 |
| McParlin, C | 2 |
| Mossop, H | 1 |
| Lie, M | 1 |
| Fernandez-Garcia, C | 1 |
| Howel, D | 1 |
| Graham, R | 1 |
| Ternent, L | 1 |
| Steel, A | 1 |
| Goudie, N | 1 |
| Nadeem, A | 1 |
| Phillipson, J | 1 |
| Shehmar, M | 1 |
| Simpson, N | 1 |
| Tuffnell, D | 1 |
| Campbell, I | 1 |
| Williams, R | 1 |
| O'Hara, ME | 1 |
| McColl, E | 1 |
| Nelson-Piercy, C | 2 |
| Tubog, TD | 2 |
| Bramble, RS | 1 |
| Drögemöller, BI | 1 |
| Wright, GEB | 1 |
| Trueman, J | 1 |
| Shaw, K | 1 |
| Staub, M | 1 |
| Chaudhry, S | 1 |
| Miao, F | 1 |
| Higginson, M | 1 |
| Groeneweg, GSS | 1 |
| Brown, J | 1 |
| Magee, LA | 1 |
| Whyte, SD | 1 |
| West, N | 1 |
| Brodie, SM | 1 |
| Jong, G' | 1 |
| Israels, S | 1 |
| Berger, H | 1 |
| Ito, S | 1 |
| Rassekh, SR | 1 |
| Sanatani, S | 1 |
| Ross, CJD | 1 |
| Carleton, BC | 1 |
| Zheng, G | 1 |
| Zhang, J | 3 |
| Liu, J | 3 |
| Chen, C | 1 |
| Zhang, L | 1 |
| Cao, F | 1 |
| Slattery, J | 1 |
| Quinten, C | 1 |
| Candore, G | 1 |
| Pinheiro, L | 1 |
| Flynn, R | 1 |
| Kurz, X | 1 |
| Nordeng, H | 1 |
| Putnam, EM | 1 |
| Hong, RA | 1 |
| Park, JM | 1 |
| Li, Y | 2 |
| Leis, A | 1 |
| Malviya, S | 1 |
| Reis, ACC | 4 |
| Jorge, BC | 4 |
| Stein, J | 4 |
| Moreira, SDS | 3 |
| Manoel, BM | 3 |
| Aquino, AM | 3 |
| Valente, LC | 3 |
| Kassuya, CAL | 3 |
| Scarano, WR | 3 |
| Arena, AC | 4 |
| da Silva Moreira, S | 1 |
| Perdão, CB | 1 |
| de Matos Manoel, B | 1 |
| Masarwe, S | 1 |
| Shvartsur, R | 1 |
| Hadar, E | 1 |
| Betesh-Abay, B | 1 |
| Peleg, N | 1 |
| Azab, AN | 1 |
| Zhao, G | 1 |
| Song, G | 1 |
| Han, T | 1 |
| Chen, Q | 1 |
| Huang, J | 1 |
| Li, A | 1 |
| Xu, W | 1 |
| Peng, Z | 1 |
| Li, Z | 1 |
| Chen, L | 1 |
| Collins, KL | 1 |
| Wilson, M | 1 |
| Vincent, EC | 1 |
| Safranek, S | 1 |
| Xiao, F | 2 |
| Wei, C | 1 |
| Chang, X | 1 |
| Zhang, Y | 1 |
| Xue, L | 1 |
| Shen, H | 1 |
| Ngan Kee, WD | 1 |
| Chen, X | 1 |
| Huybrechts, KF | 4 |
| Hernandez-Diaz, S | 5 |
| Straub, L | 2 |
| Gray, KJ | 2 |
| Zhu, Y | 3 |
| Mogun, H | 2 |
| Bateman, BT | 4 |
| Lemon, LS | 2 |
| Bodnar, LM | 2 |
| Garrard, W | 1 |
| Venkataramanan, R | 3 |
| Platt, RW | 2 |
| Marroquin, OC | 1 |
| Caritis, SN | 3 |
| Nejadi, JR | 1 |
| Shamseh, M | 1 |
| Ronasi, N | 1 |
| Birjandi, M | 1 |
| Karimi, A | 1 |
| Ostenfeld, A | 1 |
| Petersen, TS | 1 |
| Futtrup, TB | 1 |
| Andersen, JT | 1 |
| Jensen, AK | 1 |
| Westergaard, HB | 1 |
| Pedersen, LH | 1 |
| Løkkegaard, ECL | 1 |
| Nnacheta, TE | 1 |
| Onyekwulu, FA | 1 |
| Amucheazi, AO | 1 |
| Picot, C | 1 |
| Berard, A | 2 |
| Grenet, G | 1 |
| Ripoche, E | 1 |
| Cucherat, M | 1 |
| Cottin, J | 1 |
| Saban, A | 1 |
| Deruelle, P | 1 |
| Boisrame, T | 1 |
| Andrade, C | 1 |
| Chooi, C | 1 |
| Cox, JJ | 1 |
| Lumb, RS | 1 |
| Middleton, P | 1 |
| Chemali, M | 1 |
| Emmett, RS | 1 |
| Simmons, SW | 1 |
| Cyna, AM | 1 |
| MacDuffie, KE | 1 |
| Kleinhans, NM | 1 |
| Stout, K | 1 |
| Wilfond, BS | 1 |
| Qian, J | 1 |
| Liu, L | 1 |
| Zheng, X | 1 |
| Neumann, C | 1 |
| Velten, M | 1 |
| Heik-Guth, C | 1 |
| Strizek, B | 1 |
| Wittmann, M | 1 |
| Hilbert, T | 1 |
| Klaschik, S | 1 |
| Kirby, RS | 2 |
| Damkier, P | 2 |
| Kaplan, YC | 3 |
| Shechtman, S | 3 |
| Diav-Citrin, O | 3 |
| Cassina, M | 2 |
| Weber-Schoendorfer, C | 2 |
| Cleary, B | 1 |
| Hodson, K | 1 |
| Suarez, EA | 2 |
| Boggess, K | 2 |
| Engel, SM | 2 |
| Stürmer, T | 2 |
| Lund, JL | 2 |
| Jonsson Funk, M | 1 |
| Funk, MJ | 1 |
| Sakran, R | 1 |
| Arnon, J | 1 |
| Guttuso, T | 1 |
| Messing, S | 1 |
| Tu, X | 1 |
| Mullin, P | 3 |
| Shepherd, R | 1 |
| Strittmatter, C | 1 |
| Saha, S | 1 |
| Thornburg, LL | 1 |
| Ankouni, T | 1 |
| Kanawati, S | 1 |
| El Khatib, R | 1 |
| El Hassan, J | 1 |
| Itani, SE | 1 |
| Rajab, O | 1 |
| Naja, Z | 1 |
| Dormuth, CR | 1 |
| Winquist, B | 1 |
| Fisher, A | 1 |
| Wu, F | 1 |
| Reynier, P | 1 |
| Suissa, S | 1 |
| Dahl, M | 1 |
| Ma, Z | 1 |
| Lu, X | 1 |
| Raymond, CB | 1 |
| Filion, KB | 1 |
| Moriello, C | 1 |
| Paterson, JM | 1 |
| Moussa, G | 1 |
| Genest, M | 1 |
| Villeneuve, E | 1 |
| Wang, JJ | 1 |
| Bordlee, JW | 1 |
| Beakley, BD | 1 |
| Mody, R | 1 |
| McConville, AP | 1 |
| Weed, JT | 1 |
| McClure, BP | 1 |
| Foldes, PJ | 1 |
| Ma, JG | 1 |
| Kaye, AD | 1 |
| Eskander, JP | 1 |
| Zhou, C | 1 |
| Bao, Z | 1 |
| Wang, X | 2 |
| Liu, Q | 1 |
| Dallmann, A | 1 |
| Ince, I | 1 |
| Coboeken, K | 1 |
| Eissing, T | 1 |
| Hempel, G | 1 |
| Karacaer, F | 1 |
| Biricik, E | 1 |
| Ünal, İ | 1 |
| Büyükkurt, S | 1 |
| Ünlügenç, H | 1 |
| Alame, MM | 1 |
| Chamsy, DJ | 1 |
| Zaraket, H | 1 |
| Lavecchia, M | 2 |
| Chari, R | 2 |
| Campbell, S | 1 |
| Ross, S | 2 |
| Sumikura, H | 1 |
| Parker, SE | 1 |
| Van Bennekom, C | 1 |
| Anderka, M | 2 |
| Mitchell, AA | 2 |
| Oofuvong, M | 1 |
| Kunapaisal, T | 1 |
| Karnjanawanichkul, O | 1 |
| Dilokrattanaphijit, N | 1 |
| Leeratiwong, J | 1 |
| Danielsson, B | 2 |
| Webster, WS | 1 |
| Ritchie, HE | 1 |
| Ranjbar, MS | 1 |
| Sheybani, S | 1 |
| Jahanbin, F | 1 |
| Balayla, J | 1 |
| Zambelli-Weiner, A | 1 |
| Via, C | 1 |
| Yuen, M | 1 |
| Weiner, DJ | 1 |
| Kane, TD | 1 |
| Pugh, MA | 1 |
| Figueroa Gray, M | 1 |
| Hsu, C | 1 |
| Kiel, L | 1 |
| Dublin, S | 1 |
| Haas, DM | 3 |
| Patorno, E | 1 |
| Desai, RJ | 1 |
| Barnhart, ML | 1 |
| Rosenbaum, K | 1 |
| Richardson, JL | 1 |
| Keskin-Arslan, E | 1 |
| Erol-Coskun, H | 1 |
| Kennedy, D | 2 |
| Kiernan, E | 1 |
| Jones, KL | 1 |
| Sheehy, O | 1 |
| Gorgui, J | 1 |
| Zhao, JP | 1 |
| Soares de Moura, C | 1 |
| Bernatsky, S | 1 |
| Pasternak, B | 1 |
| Svanström, H | 1 |
| Hviid, A | 1 |
| Habib, AS | 1 |
| George, RB | 1 |
| McKeen, DM | 1 |
| White, WD | 1 |
| Ituk, US | 1 |
| Megalla, SA | 1 |
| Allen, TK | 1 |
| Kashifard, M | 2 |
| Basirat, Z | 1 |
| Golsorkhtabar-Amiri, M | 1 |
| Moghaddamnia, A | 1 |
| Lehmann, AS | 1 |
| Renbarger, JL | 1 |
| McCormick, CL | 1 |
| Topletz, AR | 1 |
| Rouse, C | 1 |
| Wood, MS | 1 |
| Oakes, ND | 1 |
| Roberts, M | 1 |
| Grassmann, C | 1 |
| Demirhan, A | 1 |
| Tekelioglu, YU | 1 |
| Akkaya, A | 1 |
| Ozlu, T | 1 |
| Yildiz, I | 1 |
| Bayir, H | 1 |
| Kocoglu, H | 1 |
| Duran, B | 1 |
| Colvin, L | 1 |
| Gill, AW | 1 |
| Slack-Smith, L | 1 |
| Stanley, FJ | 1 |
| Bower, C | 1 |
| Larrimer, MB | 1 |
| Dajani, NK | 1 |
| Siegel, ER | 1 |
| Eswaran, H | 1 |
| Newport, DJ | 1 |
| Stowe, ZN | 1 |
| Wang, Q | 1 |
| Zhuo, L | 1 |
| Shen, MK | 1 |
| Yu, YY | 1 |
| Yu, JJ | 1 |
| Wang, M | 1 |
| Ortiz-Gómez, JR | 1 |
| Palacio-Abizanda, FJ | 1 |
| Morillas-Ramirez, F | 1 |
| Fornet-Ruiz, I | 1 |
| Lorenzo-Jiménez, A | 1 |
| Bermejo-Albares, ML | 1 |
| Abas, MN | 1 |
| Tan, PC | 2 |
| Azmi, N | 1 |
| Omar, SZ | 2 |
| Watson, E | 1 |
| Cooper, D | 2 |
| Kung, AT | 1 |
| Yang, X | 1 |
| Vasudevan, A | 1 |
| Pratt, S | 1 |
| Hess, P | 2 |
| Furyk, JS | 1 |
| Meek, R | 1 |
| McKenzie, S | 1 |
| Koren, G | 7 |
| Oliveira, LG | 1 |
| Capp, SM | 1 |
| You, WB | 1 |
| Riffenburgh, RH | 1 |
| Carstairs, SD | 2 |
| Clark, SM | 1 |
| Dutta, E | 1 |
| Hankins, GD | 2 |
| Imeh, A | 1 |
| Olaniyi, O | 1 |
| Simeon, O | 1 |
| Omotola, O | 1 |
| Wikner, BN | 1 |
| Källén, B | 1 |
| Cohen, R | 1 |
| Shlomo, M | 1 |
| Dil, DN | 1 |
| Dinavitser, N | 1 |
| Berkovitch, M | 1 |
| Lin, X | 1 |
| Du, Y | 1 |
| Tang, Y | 1 |
| Zeng, K | 1 |
| Ni, J | 1 |
| Zhou, J | 1 |
| Maltepe, C | 4 |
| Madjunkova, S | 1 |
| Cunningham, K | 1 |
| Oliveira, L | 1 |
| Capp, S | 1 |
| Elkomy, MH | 1 |
| Sultan, P | 1 |
| Carvalho, B | 1 |
| Peltz, G | 1 |
| Wu, M | 1 |
| Clavijo, C | 1 |
| Galinkin, JL | 1 |
| Drover, DR | 1 |
| Fattahi, Z | 1 |
| Hadavi, SM | 1 |
| Sahmeddini, MA | 1 |
| Mayhall, EA | 1 |
| Gray, R | 1 |
| Lopes, V | 1 |
| Matteson, KA | 1 |
| Koju, RB | 1 |
| Gurung, BS | 1 |
| Dongol, Y | 1 |
| Fejzo, MS | 2 |
| MacGibbon, K | 2 |
| Marciniak, A | 1 |
| Owczuk, R | 1 |
| Wujtewicz, M | 1 |
| Preis, K | 1 |
| Majdyło, K | 1 |
| Mills, JR | 1 |
| Greene, DN | 1 |
| Bainton, J | 1 |
| Lorey, TS | 1 |
| Baumann, NA | 1 |
| Nivatpumin, P | 1 |
| Thamvittayakul, V | 1 |
| Siminerio, LL | 1 |
| MacGibbon, KW | 1 |
| Mullin, PM | 1 |
| Boelig, RC | 1 |
| Barton, SJ | 1 |
| Saccone, G | 1 |
| Kelly, AJ | 1 |
| Edwards, SJ | 1 |
| Berghella, V | 1 |
| Zhang, H | 1 |
| Hebert, MF | 1 |
| Reichmann, JP | 3 |
| Kirkbride, MS | 2 |
| El Khouly, NI | 1 |
| Meligy, AM | 1 |
| Loh, MH | 1 |
| Lean, LL | 1 |
| Ng, BSW | 1 |
| Loh, WN | 1 |
| O'Donnell, A | 1 |
| Robson, SC | 1 |
| Beyer, F | 1 |
| Moloney, E | 1 |
| Bryant, A | 1 |
| Bradley, J | 1 |
| Muirhead, CR | 1 |
| Newbury-Birch, D | 1 |
| Norman, J | 1 |
| Shaw, C | 1 |
| Simpson, E | 1 |
| Swallow, B | 1 |
| Yates, L | 1 |
| Vale, L | 1 |
| Fejzo, M | 1 |
| Edlavitch, SA | 1 |
| Taylor, LG | 1 |
| Bird, ST | 1 |
| Sahin, L | 1 |
| Tassinari, MS | 1 |
| Greene, P | 1 |
| Reichman, ME | 1 |
| Andrade, SE | 1 |
| Haffenreffer, K | 1 |
| Toh, S | 1 |
| Kamendi, HW | 1 |
| Cheng, Q | 1 |
| Dergacheva, O | 1 |
| Gorini, C | 1 |
| Jameson, HS | 1 |
| McIntosh, JM | 1 |
| Mendelowitz, D | 1 |
| Jennings-Sanders, A | 1 |
| Tamdee, D | 1 |
| Charuluxananan, S | 3 |
| Punjasawadwong, Y | 1 |
| Tawichasri, C | 1 |
| Patumanond, J | 1 |
| Sriprajittichai, P | 1 |
| Tan, T | 1 |
| Ojo, R | 1 |
| Immani, S | 1 |
| Choroszczak, P | 1 |
| Carey, M | 1 |
| Sharma, R | 1 |
| Panda, A | 1 |
| Siddik-Sayyid, SM | 3 |
| Yazbeck-Karam, VG | 1 |
| Zahreddine, BW | 1 |
| Adham, AM | 1 |
| Dagher, CM | 1 |
| Saasouh, WA | 1 |
| Aouad, MT | 2 |
| Fujii, Y | 1 |
| Aouad, M | 1 |
| Hellwig, K | 1 |
| Schimrigk, S | 1 |
| Chan, A | 1 |
| Epplen, J | 1 |
| Gold, R | 1 |
| Klauser, CK | 1 |
| Fox, NS | 1 |
| Istwan, N | 1 |
| Rhea, D | 1 |
| Rebarber, A | 1 |
| Desch, C | 1 |
| Palmer, B | 1 |
| Saltzman, D | 1 |
| El-Deeb, AM | 1 |
| Ahmady, MS | 1 |
| Sahoo, T | 1 |
| SenDasgupta, C | 1 |
| Goswami, A | 1 |
| Hazra, A | 1 |
| Louik, C | 1 |
| Werler, MM | 1 |
| Rasmussen, SA | 1 |
| Ferreira, E | 1 |
| Gillet, M | 1 |
| Lelièvre, J | 1 |
| Bussières, JF | 1 |
| Downs, AJ | 1 |
| Poonawala, Y | 1 |
| Selvan, D | 1 |
| Jagannathan, V | 1 |
| Puttaswamy, RK | 1 |
| Valap, S | 1 |
| Pierson, R | 1 |
| Das, B | 1 |
| Hodges, M | 1 |
| Hodgson, R | 1 |
| Chaudhari, S | 1 |
| Botros, S | 1 |
| Moore, P | 1 |
| Raymond, SH | 1 |
| Siu, SS | 2 |
| Yip, SK | 1 |
| Cheung, CW | 1 |
| Lau, TK | 2 |
| Kyokong, O | 2 |
| Somboonviboon, W | 2 |
| Narasethakamol, A | 2 |
| Promlok, P | 2 |
| Bier, JC | 1 |
| Dethy, S | 1 |
| Hildebrand, J | 1 |
| Jacquy, J | 1 |
| Manto, M | 1 |
| Martin, JJ | 1 |
| Seeldrayers, P | 1 |
| Quinla, JD | 1 |
| Hill, DA | 1 |
| Schumann, R | 1 |
| Hudcova, J | 1 |
| Wells, J | 1 |
| Paech, MJ | 1 |
| Evans, SF | 1 |
| Einarson, A | 1 |
| Navioz, Y | 1 |
| Tan, MP | 1 |
| Spiegel, JE | 1 |
| Kang, V | 1 |
| Kunze, L | 1 |
| Sarvela, PJ | 1 |
| Halonen, PM | 1 |
| Soikkeli, AI | 1 |
| Kainu, JP | 1 |
| Korttila, KT | 1 |
| Chan, MT | 1 |
| Peixoto, AJ | 1 |
| Celich, MF | 1 |
| Zardo, L | 1 |
| Peixoto Filho, AJ | 1 |
| Marchi, N | 1 |
| Guiso, G | 1 |
| Caccia, S | 1 |
| Rizzi, M | 1 |
| Gagliardi, B | 1 |
| Noé, F | 1 |
| Ravizza, T | 1 |
| Bassanini, S | 1 |
| Chimenti, S | 1 |
| Battaglia, G | 1 |
| Vezzani, A | 1 |
| Taha, SK | 1 |
| Azar, MS | 1 |
| Hakki, MA | 1 |
| Kaddoum, RN | 1 |
| Nasr, VG | 1 |
| Yazbek, VG | 1 |
| Baraka, AS | 1 |
| Gulhas, N | 1 |
| Erdil, FA | 1 |
| Sagir, O | 1 |
| Gedik, E | 1 |
| Togal, T | 1 |
| Begec, Z | 1 |
| Ersoy, MO | 1 |
| Butkevich, IP | 1 |
| Mikhaĭlenko, VA | 1 |
| Makukhina, GV | 1 |
| Han, DW | 1 |
| Hong, SW | 1 |
| Kwon, JY | 1 |
| Lee, JW | 1 |
| Kim, KJ | 1 |
| Harnett, MJ | 1 |
| O'Rourke, N | 1 |
| Walsh, M | 1 |
| Carabuena, JM | 1 |
| Segal, S | 1 |
| Kwon, P | 1 |
| Lefkowitz, W | 1 |
| Schwörer, H | 1 |
| Ramadori, G | 1 |
| World, MJ | 1 |
| Crighton, IM | 1 |
| Hobbs, GJ | 1 |
| Reid, MF | 1 |
| Pan, PH | 2 |
| Moore, CH | 2 |
| Tincello, DG | 1 |
| Johnstone, MJ | 1 |
| Moiseiwitsch, JR | 1 |
| Lauder, JM | 1 |
| Sullivan, CA | 1 |
| Johnson, CA | 1 |
| Roach, H | 1 |
| Martin, RW | 1 |
| Stewart, DK | 1 |
| Morrison, JC | 1 |
| Arango, HA | 1 |
| Kalter, CS | 1 |
| Decesare, SL | 1 |
| Fiorica, JV | 1 |
| Lyman, GH | 1 |
| Spellacy, WN | 1 |
| Monagle, J | 1 |
| Barnes, R | 1 |
| Goodchild, C | 1 |
| Hewitt, M | 1 |
| Ditto, A | 1 |
| Morgante, G | 1 |
| la Marca, A | 1 |
| De Leo, V | 1 |
| Manullang, TR | 1 |
| Viscomi, CM | 1 |
| Pace, NL | 1 |
| Yeh, HM | 1 |
| Chen, LK | 1 |
| Lin, CJ | 1 |
| Chan, WH | 1 |
| Chen, YP | 1 |
| Lin, CS | 1 |
| Sun, WZ | 1 |
| Wang, MJ | 1 |
| Tsai, SK | 1 |
| Abouleish, EI | 1 |
| Rashid, S | 1 |
| Haque, S | 1 |
| Giezentanner, A | 1 |
| Joynton, P | 1 |
| Chuang, AZ | 1 |
| Cherian, VT | 1 |
| Smith, I | 1 |
| Sanai, L | 1 |
| Yazigi, A | 1 |
| Chalhoub, V | 1 |
| Madi-Jebara, S | 1 |
| Haddad, F | 1 |
| Hayek, G | 1 |
| Guikontes, E | 1 |
| Spantideas, A | 1 |
| Diakakis, J | 1 |
| Alon, E | 1 |
| Himmelseher, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A PROSPECTIVE, RANDOMIZED, DOUBLE-BLINDED STUDY OF THE EFFECT OF A STANDARD DOSE OF INTRAVENOUS ONDANSETRON ON THE EFFECTIVE DOSE IN 50% OF SUBJECTS OF PROPHYLACTIC NOREPINEPHRINE INFUSIONS FOR PREVENTING SPINAL ANESTHESIA-INDUCED HYPOTENSION DURING CESAR[NCT04703088] | Phase 3 | 60 participants (Anticipated) | Interventional | 2021-06-30 | Not yet recruiting | ||
| Validating the Effect of Ondansetron and Mirtazapine in Treating Hyperemesis Gravidarum: A Double-Blind Randomised Placebo-Controlled Multicentre Trial[NCT03785691] | Phase 2 | 58 participants (Actual) | Interventional | 2019-03-01 | Terminated (stopped due to Recruiting difficulties) | ||
| The Effect of Intravenous Infusion of Tramadol-ondansetron on Recovery After Caesarean Section. A Prospective, Observational and Non-inferiority Study Against Epidural Analgesia.[NCT05879536] | 312 participants (Anticipated) | Observational | 2023-05-23 | Recruiting | |||
| Evaluation of the Efficacy of 6% Hydroxyethyl Starch (HES, 130/0.4) in Normal Saline Compared to Ringer's Lactate Solution for the Prevention of Hypotension During Spinal Anesthesia for Cesarean Section[NCT00694343] | Phase 4 | 167 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| The Time Required to Remain Sitting After Spinal Anesthesia for 50% of Patients to Not Experience Hypotension[NCT01561274] | Phase 2 | 50 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| The Oxygenation of the Brain During Caesarean Section. A Comparison of Ephedrine Versus Phenylephrine[NCT01509521] | Phase 4 | 24 participants (Anticipated) | Interventional | 2012-02-29 | Completed | ||
| Electrical Acupoint Stimulation Alleviates Hypotension After Spinal Anesthesia in Parturients: a Prospective Randomized Controlled Clinical Trial[NCT05724095] | 90 participants (Actual) | Interventional | 2023-02-20 | Completed | |||
| Comparison of Gabapentin and Metoclopramide for Treating Hyperemesis Gravidarum[NCT02163434] | Phase 2 | 31 participants (Actual) | Interventional | 2014-06-30 | Completed | ||
| Prevalence and Burden of Nausea and Vomiting in Pregnant Women in Switzerland: Survey Purity 2022[NCT06055192] | 200 participants (Anticipated) | Observational | 2023-09-30 | Not yet recruiting | |||
| Enhanced Recovery at Cesarean Birth to Improve Postoperative Outcomes and Reduce Postoperative Length of Stay[NCT02956616] | Phase 2 | 118 participants (Actual) | Interventional | 2017-09-01 | Completed | ||
| The Effect of Adding Metoclopramide and Ondansetron to a Prophylactic Phenylephrine Infusion for the Management of Nausea and Vomiting Associated With Spinal Anesthesia for Cesarean Section[NCT01216410] | 306 participants (Actual) | Interventional | 2008-12-31 | Completed | |||
| The Effect of Antibiotic Prophylaxis Timing on Intraoperative Nausea and Vomiting in Patients Undergoing Cesarean Section Under Regional Anesthesia.[NCT04697277] | Phase 4 | 120 participants (Anticipated) | Interventional | 2015-08-20 | Recruiting | ||
| Does Prophylactic Ondansetron Reduce Norepinephrine Consumption in Patients Undergoing Caesarean Section With Spinal Anesthesia?[NCT02928601] | Phase 4 | 108 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Is Zofran Superior to Pyridoxine at Reducing Nausea and Vomiting in Pregnancy[NCT01668069] | 36 participants (Actual) | Interventional | 2012-10-31 | Completed | |||
| Prevention of Neonatal Abstinence Syndrome[NCT01801475] | Phase 1/Phase 2 | 100 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| The Efficacy of Neostigmine as an Adjuvant to Bupivacaine for Intrathecal Block in Reducing the Incidence and Severity of Post-Dural Puncture Headache for Parturients Scheduled for Elective Caesarean Section[NCT03587441] | Phase 4 | 240 participants (Actual) | Interventional | 2018-08-04 | Completed | ||
| Role of Dexamethasone or Ondansetron in the Quality of Recovery After Intrathecal Morphine Administration in Patients Undergoing Lower Limb Surgery.[NCT03035942] | Phase 4 | 135 participants (Actual) | Interventional | 2017-01-02 | Completed | ||
| Effect of Intravenous Granisetron on Incidence and Severity of Intrathecal Morphine Induced Pruritus in Elective Cesarean Section[NCT03483870] | Phase 2 | 80 participants (Actual) | Interventional | 2018-06-01 | Completed | ||
| The Effect of Adjuvant Hypnosis Added to Conventional Therapy on Nausea and Vomiting in Hyperemesis Gravidarum: A Prospective Randomized Study[NCT04828967] | 41 participants (Actual) | Interventional | 2017-01-01 | Completed | |||
| The Use of P6 Acupressure for the Reduction of Intraoperative and Postoperative Nausea and Vomiting in Women Undergoing Cesarean Delivery: a Randomized Trial[NCT04799587] | 200 participants (Actual) | Interventional | 2021-05-26 | Completed | |||
| The Efficacy and Safety of Ramosetron in Patients Undergoing Off Pump Coronary Artery Bypass Surgery[NCT02139241] | 114 participants (Actual) | Interventional | 2013-06-30 | Completed | |||
| Prophylaxis Ephedrine or Ondansetron Prevents Hypotension After Spinal Anesthesia for Cesarean Section; a Randomized, Double Blinded, Placebo Controlled Trial[NCT02194192] | 168 participants (Actual) | Interventional | 2014-07-31 | Completed | |||
| Association Between Preoperative Shock Index and Hypotension After Spinal Anaesthesia for Non-elective Caesarean Section: A Prospective Observational Study[NCT04692870] | 337 participants (Actual) | Observational | 2021-01-06 | Completed | |||
| Quality of Recovery Following Administration of Transverse Abdominus Plane (TAP) Catheter as Compared to Intrathecal Morphine After Cesarean Delivery Under Spinal Anesthesia: a Prospective, Randomized Trial[NCT01593280] | 80 participants (Anticipated) | Interventional | 2012-05-31 | Recruiting | |||
| Is the Application of Scopolamine Patch With or Without Intra-operative Acupressure Point P6 Stimulation More Effective Than Intra-operative Acupressure Point P6 Stimulation Alone?[NCT02960113] | Phase 4 | 240 participants (Actual) | Interventional | 2016-05-31 | Completed | ||
| IRB-HSR# 14583: Intravenous Ondansetron to Attenuate the Hypotensive, Bradycardic Response to Spinal Anesthesia in Healthy Parturients[NCT01414777] | Phase 2/Phase 3 | 68 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| Comparison Between Ondansetron 8 mg and Lidocain 40 mg in Preventing Pain Due to Propofol Injection[NCT03134612] | Phase 2 | 104 participants (Actual) | Interventional | 2016-07-31 | Completed | ||
| Randomized Double Control Study to Assess the Efficacy of Administering 1 ml of Glycopyrrolate With the Spinal Dose in Minimizing Nausea and Vomiting in Patients Undergoing Cesarean Section Under Spinal Anesthesia[NCT02872935] | Phase 4 | 22 participants (Actual) | Interventional | 2015-05-15 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Score range: 6-30 with higher score indicating a worse outcome. (NCT02163434)
Timeframe: 1 week
| Intervention | units on a scale (Mean) |
|---|---|
| Gabapentin | 6.35 |
| Metoclopramide | 13.22 |
Score range: 2-10 with higher score indicating a worse outcome. (NCT02163434)
Timeframe: 1 week
| Intervention | units on a scale (Mean) |
|---|---|
| Gabapentin | 2.01 |
| Metoclopramide | 3.69 |
Score range: 0-15 with higher score indicating a better outcome. (NCT02163434)
Timeframe: 1 week
| Intervention | units on a scale (Mean) |
|---|---|
| Gabapentin | 7.86 |
| Metoclopramide | 4.01 |
Scores: 0=no, 1=yes. Thus, a higher score indicates a better outcome. (NCT02163434)
Timeframe: 1 week
| Intervention | units on a scale (Mean) |
|---|---|
| Gabapentin | 0.67 |
| Metoclopramide | 0.14 |
Score range: 0-4 with higher score indicating a better outcome. (NCT02163434)
Timeframe: 1 week
| Intervention | units on a scale (Mean) |
|---|---|
| Gabapentin | 2.22 |
| Metoclopramide | 0.63 |
(NCT02163434)
Timeframe: 1 week
| Intervention | Participants (Count of Participants) |
|---|---|
| Gabapentin | 5 |
| Metoclopramide | 5 |
Number of patients discharged on postoperative Day #2 (NCT02956616)
Timeframe: Until patient's day of hospital discharge or a maximum of one month from cesarean delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Enhanced Recovery | 5 |
| Routine Perioperative Care | 2 |
Postoperative Length of Hospital Stay in Hours from time of surgery (NCT02956616)
Timeframe: Until patient's day of hospital discharge or a maximum of one month from cesarean delivery
| Intervention | Hours (Median) |
|---|---|
| Enhanced Recovery | 73.58 |
| Routine Perioperative Care | 75.50 |
The amount of postoperative pain medication required for each patient in Morphine Milligram Equivalents (NCT02956616)
Timeframe: Until patient's day of hospital discharge or a maximum of one month from cesarean delivery
| Intervention | Morphine Milligram Equivalents (Mean) |
|---|---|
| Enhanced Recovery | 117.16 |
| Routine Perioperative Care | 119.38 |
All patients will be queried regarding whether breastfeeding was initiated after cesarean birth and how soon after birth (NCT02956616)
Timeframe: Until patient's day of hospital discharge or a maximum of one month from cesarean delivery
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Breastfeeding | Bottlefeeding | Both Breastfeeding and Bottlefeeding | |
| Enhanced Recovery | 39 | 4 | 15 |
| Routine Perioperative Care | 29 | 2 | 29 |
Comparison of intraoperative nausea and vomiting between the 3 groups. (NCT01216410)
Timeframe: Intraoperatively
| Intervention | participants (Number) |
|---|---|
| Combination Group | 23 |
| Metoclopramide | 31 |
| Phenylephrine Infusion | 49 |
The number of patients with systolic blood pressure decrease to less than 20 % of baseline intraoperatively (NCT01216410)
Timeframe: Intraoperatively
| Intervention | participants with SBP< 20 % baseline (Number) |
|---|---|
| Combination Group | 16 |
| Metoclopramide | 19 |
| Phenylephrine Infusion | 16 |
(NCT01216410)
Timeframe: 0-24 hrs
| Intervention | participants (Number) |
|---|---|
| Combination Group | 95 |
| Metoclopramide | 93 |
| Phenylephrine Infusion | 97 |
1=very satisfied, 2=somewhat satisfied, 3= neither satisfied nor dissatisfied, 4=somewhat dissatisfied, 5= very dissatisfied. Number of very satisfied subjects posted. (NCT01216410)
Timeframe: 24 h
| Intervention | participants (Number) |
|---|---|
| Combination Group | 94 |
| Metoclopramide | 85 |
| Phenylephrine Infusion | 87 |
(NCT01216410)
Timeframe: 0-2h, 2-6h, 6-24h
| Intervention | participants (Number) | ||
|---|---|---|---|
| 0-2 hrs PONV | 2-6 hrs PONV | 6-24 hrs PONV | |
| Combination Group | 20 | 28 | 22 |
| Metoclopramide | 33 | 35 | 26 |
| Phenylephrine Infusion | 39 | 41 | 22 |
This is a mathematical estimation of the clearance for ondasetron as calculated by NONMEM. (NCT01801475)
Timeframe: 8 hours for women; 48 hours for neonate.
| Intervention | L/hr (Mean) |
|---|---|
| Women - Pregnant/Non-pregnant | 21.8 |
| Neonates | NA |
This is an estimated pharmacokinetic parameter as calculated by NONMEM. (NCT01801475)
Timeframe: 8 hours for women; 48 hours for neonate.
| Intervention | Liters (Mean) |
|---|---|
| Women - Pregnant/Non-pregnant | 27.9 |
| Neonates | NA |
The occurrence of PONV will be registered during the PACU (NCT03035942)
Timeframe: 4h
| Intervention | Participants (Count of Participants) |
|---|---|
| O Group | 3 |
| D Group | 9 |
| S Group | 9 |
The occurrence of localized or generalized itching (patients who answered yes or no) (NCT03035942)
Timeframe: 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| O Group | 4 |
| D Group | 7 |
| S Group | 8 |
Pain were assessed every 15 minutes during postanesthesia care unit, where zero meant no pain and 10 the worst imaginable pain (higher values represent worse outcome). Twenty four hours after surgery, patients were asked to describe the highest pain score (NRS) during ward stay. (NCT03035942)
Timeframe: 24 hours
| Intervention | Score on a scale (NRS) (Median) |
|---|---|
| D Group | 0 |
| O Group | 5 |
| S Group | 2 |
Quality of Recovery Questionnaire (QoR-40). Minimum score 40 (very poor quality of recovery) and maximun score 200 (excellent quality of recovery). Higher scores mean better outcome (NCT03035942)
Timeframe: Twenty four hours after surgery by a blinded investigator
| Intervention | Score on a scale (Median) |
|---|---|
| O Group | 184 |
| D Group | 187 |
| S Group | 185 |
Patients offer their subjective assessments of the level of nausea on a scale of 0-10 (0 = no nausea, 10 = worst nausea ever experienced) after eversion of the uterus. The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea in each group at this point. Patients that report nausea (1 or more on our scale) will be recorded as that they have experienced nausea. (NCT02960113)
Timeframe: After eversion of the uterus until replacement of the uterus
| Intervention | units on a scale (Mean) |
|---|---|
| Scopolamine Patch | 1.28 |
| Acupressure Point P6 | 1.09 |
| Scopolamine Patch + Acupressure Point P6 | 1.40 |
Patients offer their subjective assessments of the level of nausea on a scale of 0-10 (0 = no nausea, 10 = worst nausea ever experienced) after replacement of the uterus. The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea in each group at this point. Patients that report nausea (1 or more on our scale) will be recorded as that they have experienced nausea. (NCT02960113)
Timeframe: After replacement of the uterus and to the next 15 minutes
| Intervention | units on a scale (Mean) |
|---|---|
| Scopolamine Patch | 2.19 |
| Acupressure Point P6 | 2.19 |
| Scopolamine Patch + Acupressure Point P6 | 2.51 |
Patients offer their subjective assessments of the level of nausea on a scale of 0-10 (0 = no nausea, 10 = worst nausea ever experienced) after the administration of the regional anesthesia medications. The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea in each group at this point. Patients that report nausea (1 or more on our scale) will be recorded as that they have experienced nausea. (NCT02960113)
Timeframe: From administration of anaesthesia until eversion of uterus
| Intervention | units on a scale (Mean) |
|---|---|
| Scopolamine Patch | 2.71 |
| Acupressure Point P6 | 2.57 |
| Scopolamine Patch + Acupressure Point P6 | 2.84 |
Patients offer their subjective assessments of the level of nausea on a scale of 0-10 (0 = no nausea, 10 = worst nausea ever experienced) upon arrival to the post-operative recovery room. The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea in each group at this point. Patients that report nausea (1 or more on our scale) will be recorded as that they have experienced nausea. (NCT02960113)
Timeframe: 15 minutes after replacement of the uterus to arrival at post-anaesthesia care unit
| Intervention | units on a scale (Mean) |
|---|---|
| Scopolamine Patch | 0.18 |
| Acupressure Point P6 | 0.25 |
| Scopolamine Patch + Acupressure Point P6 | 0.23 |
The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea at any point during the surgical procedure in each group. (NCT02960113)
Timeframe: Throughout the entire surgical procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Scopolamine Patch | 40 |
| Acupressure Point P6 | 39 |
| Scopolamine Patch + Acupressure Point P6 | 46 |
The investigators will perform objective assessments of whether or not the patients have vomited during the procedure. The investigators will then analyze if there is a statistically significant difference between the number of patients that vomit in each group. (NCT02960113)
Timeframe: Throughout the surgical procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Scopolamine Patch | 24 |
| Acupressure Point P6 | 25 |
| Scopolamine Patch + Acupressure Point P6 | 31 |
Objective assessments of whether or not the patients have vomited at this point in the surgical procedure will be done. The investigators will analyze if there is a statistically significant difference between the number of patients that vomit in each group. (NCT02960113)
Timeframe: After eversion of to replacement of the uterus
| Intervention | Participants (Count of Participants) |
|---|---|
| Scopolamine Patch | 8 |
| Acupressure Point P6 | 6 |
| Scopolamine Patch + Acupressure Point P6 | 9 |
Objective assessments of whether or not the patients have vomited at this point in the surgical procedure will be done. The investigators will analyze if there is a statistically significant difference between the number of patients that vomit in each group. (NCT02960113)
Timeframe: After replacement of the uterus and for next 15 minutes
| Intervention | Participants (Count of Participants) |
|---|---|
| Scopolamine Patch | 10 |
| Acupressure Point P6 | 15 |
| Scopolamine Patch + Acupressure Point P6 | 12 |
Objective assessments of whether or not the patients have vomited at this point in the surgical procedure will be done. The investigators will analyze if there is a statistically significant difference between the number of patients that vomit in each group. (NCT02960113)
Timeframe: After the administration of the regional anesthesia medications until eversion of the uterus
| Intervention | Participants (Count of Participants) |
|---|---|
| Scopolamine Patch | 20 |
| Acupressure Point P6 | 15 |
| Scopolamine Patch + Acupressure Point P6 | 20 |
Objective assessments of whether or not the patients have vomited at this point in the surgical procedure will be done. The investigators will analyze if there is a statistically significant difference between the number of patients that vomit in each group. (NCT02960113)
Timeframe: From 15 minutes after replacement of the uterus until arrival at the post-anaesthesia care unit
| Intervention | Participants (Count of Participants) |
|---|---|
| Scopolamine Patch | 1 |
| Acupressure Point P6 | 1 |
| Scopolamine Patch + Acupressure Point P6 | 4 |
Patients are asked their nausea and vomiting treatment satisfaction (0 = Not Satisfied, 10 = Extremely Satisfied). Patients are also asked their overall satisfaction with the procedure (0 = Not Satisfied, 10 = Extremely Satisfied). (NCT02960113)
Timeframe: Throughout the surgical procedure
| Intervention | units on a scale (Mean) |
|---|---|
| Scopolamine Patch | 9.29 |
| Acupressure Point P6 | 8.96 |
| Scopolamine Patch + Acupressure Point P6 | 9.59 |
This measure is observed by care team. Reported as vomiting, yes or no. (NCT02872935)
Timeframe: From the administration of the spinal anesthesia to delivery of baby; Total time 90minutes
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo: Normal Saline | 4 |
| Glycopyrrolate Group | 2 |
Did the subject report nausea? The subject will respond with yes or no. (NCT02872935)
Timeframe: From the administration of the spinal anesthesia to delivery of baby - Total time 90minutes
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo: Normal Saline | 8 |
| Glycopyrrolate Group | 7 |
24 reviews available for ondansetron and Pregnancy
| Article | Year |
|---|---|
Ondansetron for Shivering after Spinal Anesthesia in Cesarean Delivery: A Systematic Review and Meta-analysis.
Topics: Anesthesia, Spinal; Cesarean Section; Double-Blind Method; Female; Humans; Ondansetron; Pregnancy; S | 2022 |
A meta-analysis of randomized controlled trials: efficiency and safety of ondansetron in preventing post-anesthesia shivering during cesarean section.
Topics: Anesthesia; Anesthesia, Spinal; Cesarean Section; Double-Blind Method; Female; Humans; Hypotension; | 2023 |
Efficacy of pharmacological therapies for preventing post-dural puncture headaches in obstetric patients: a Bayesian network meta-analysis of randomized controlled trials.
Topics: Bayes Theorem; Cesarean Section; Female; Humans; Network Meta-Analysis; Ondansetron; Post-Dural Punc | 2023 |
Risk of malformation after ondansetron in pregnancy: An updated systematic review and meta-analysis.
Topics: Abnormalities, Drug-Induced; Antiemetics; Cleft Lip; Cleft Palate; Female; Humans; Ondansetron; Preg | 2020 |
Contextualizing Potential Risks of Medications in Pregnancy for the Newborn-the Case of Ondansetron.
Topics: Antiemetics; Female; Humans; Infant, Newborn; Maternal Exposure; Ondansetron; Pregnancy; Pregnancy C | 2020 |
Major Congenital Malformation Risk After First Trimester Gestational Exposure to Oral or Intravenous Ondansetron.
Topics: Abnormalities, Drug-Induced; Administration, Intravenous; Administration, Oral; Antiemetics; Female; | 2020 |
Techniques for preventing hypotension during spinal anaesthesia for caesarean section.
Topics: Anesthesia, Obstetrical; Anesthesia, Spinal; Antiemetics; Cesarean Section; Colloids; Crystalloid So | 2020 |
Techniques for preventing hypotension during spinal anaesthesia for caesarean section.
Topics: Anesthesia, Obstetrical; Anesthesia, Spinal; Antiemetics; Cesarean Section; Colloids; Crystalloid So | 2020 |
Techniques for preventing hypotension during spinal anaesthesia for caesarean section.
Topics: Anesthesia, Obstetrical; Anesthesia, Spinal; Antiemetics; Cesarean Section; Colloids; Crystalloid So | 2020 |
Techniques for preventing hypotension during spinal anaesthesia for caesarean section.
Topics: Anesthesia, Obstetrical; Anesthesia, Spinal; Antiemetics; Cesarean Section; Colloids; Crystalloid So | 2020 |
Techniques for preventing hypotension during spinal anaesthesia for caesarean section.
Topics: Anesthesia, Obstetrical; Anesthesia, Spinal; Antiemetics; Cesarean Section; Colloids; Crystalloid So | 2020 |
Techniques for preventing hypotension during spinal anaesthesia for caesarean section.
Topics: Anesthesia, Obstetrical; Anesthesia, Spinal; Antiemetics; Cesarean Section; Colloids; Crystalloid So | 2020 |
Techniques for preventing hypotension during spinal anaesthesia for caesarean section.
Topics: Anesthesia, Obstetrical; Anesthesia, Spinal; Antiemetics; Cesarean Section; Colloids; Crystalloid So | 2020 |
Techniques for preventing hypotension during spinal anaesthesia for caesarean section.
Topics: Anesthesia, Obstetrical; Anesthesia, Spinal; Antiemetics; Cesarean Section; Colloids; Crystalloid So | 2020 |
Techniques for preventing hypotension during spinal anaesthesia for caesarean section.
Topics: Anesthesia, Obstetrical; Anesthesia, Spinal; Antiemetics; Cesarean Section; Colloids; Crystalloid So | 2020 |
Techniques for preventing hypotension during spinal anaesthesia for caesarean section.
Topics: Anesthesia, Obstetrical; Anesthesia, Spinal; Antiemetics; Cesarean Section; Colloids; Crystalloid So | 2020 |
Techniques for preventing hypotension during spinal anaesthesia for caesarean section.
Topics: Anesthesia, Obstetrical; Anesthesia, Spinal; Antiemetics; Cesarean Section; Colloids; Crystalloid So | 2020 |
Techniques for preventing hypotension during spinal anaesthesia for caesarean section.
Topics: Anesthesia, Obstetrical; Anesthesia, Spinal; Antiemetics; Cesarean Section; Colloids; Crystalloid So | 2020 |
Techniques for preventing hypotension during spinal anaesthesia for caesarean section.
Topics: Anesthesia, Obstetrical; Anesthesia, Spinal; Antiemetics; Cesarean Section; Colloids; Crystalloid So | 2020 |
Techniques for preventing hypotension during spinal anaesthesia for caesarean section.
Topics: Anesthesia, Obstetrical; Anesthesia, Spinal; Antiemetics; Cesarean Section; Colloids; Crystalloid So | 2020 |
Techniques for preventing hypotension during spinal anaesthesia for caesarean section.
Topics: Anesthesia, Obstetrical; Anesthesia, Spinal; Antiemetics; Cesarean Section; Colloids; Crystalloid So | 2020 |
Techniques for preventing hypotension during spinal anaesthesia for caesarean section.
Topics: Anesthesia, Obstetrical; Anesthesia, Spinal; Antiemetics; Cesarean Section; Colloids; Crystalloid So | 2020 |
Comparison of Pregnancy Outcomes of Patients Treated With Ondansetron vs Alternative Antiemetic Medications in a Multinational, Population-Based Cohort.
Topics: Abortion, Spontaneous; Adult; Antiemetics; Canada; Cohort Studies; Congenital Abnormalities; Databas | 2021 |
Efficacy of ondansetron for spinal anesthesia during cesarean section: a meta-analysis of randomized trials.
Topics: Adult; Anesthesia, Spinal; Anesthetics, Local; Antiemetics; Bradycardia; Cesarean Section; Female; H | 2018 |
Ondansetron in Pregnancy and the Risk of Congenital Malformations: A Systematic Review.
Topics: Antiemetics; Congenital Abnormalities; Female; Humans; Hyperemesis Gravidarum; Ondansetron; Pregnanc | 2018 |
Effects of Ondansetron on Attenuating Spinal Anesthesia–Induced Hypotension and Bradycardia in Obstetric and Nonobstetric Subjects: A Systematic Review and Meta-Analysis.
Topics: Anesthesia, Spinal; Antiemetics; Bradycardia; Delivery, Obstetric; Female; Humans; Hypotension; Infu | 2017 |
Use of ondansetron during pregnancy and the risk of major congenital malformations: A systematic review and meta-analysis.
Topics: Abnormalities, Drug-Induced; Antiemetics; Case-Control Studies; Cohort Studies; Female; Humans; Onda | 2019 |
Medications that Cause Fetal Anomalies and Possible Prevention Strategies.
Topics: Abnormalities, Drug-Induced; Acetaminophen; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Analg | 2019 |
The outpatient management and special considerations of nausea and vomiting in pregnancy.
Topics: Ambulatory Care; Antiemetics; Diet Therapy; Doxylamine; Female; Fluid Therapy; Gastroesophageal Refl | 2014 |
Ondansetron Use in Pregnancy and Birth Defects: A Systematic Review.
Topics: Abnormalities, Drug-Induced; Antiemetics; Female; Humans; Hyperemesis Gravidarum; Infant, Newborn; O | 2016 |
Interventions for treating hyperemesis gravidarum.
Topics: Acupuncture Therapy; Adrenal Cortex Hormones; Antiemetics; Female; Humans; Hydrocortisone; Hyperemes | 2016 |
Treatments for Hyperemesis Gravidarum and Nausea and Vomiting in Pregnancy: A Systematic Review.
Topics: Acupuncture; Adrenal Cortex Hormones; Antiemetics; Doxylamine; Female; Histamine Antagonists; Humans | 2016 |
Publishing negative findings and the challenge of avoiding type II errors in studies of suspect teratogens: Example of a recent ondansetron publication.
Topics: Antiemetics; Female; Humans; Hyperemesis Gravidarum; Ondansetron; Pregnancy; Pregnancy Outcome; Rese | 2017 |
Prevention of nausea and vomiting during termination of pregnancy.
Topics: Abortion, Therapeutic; Antiemetics; Benzimidazoles; Dexamethasone; Dilatation and Curettage; Droperi | 2010 |
Contemporary approaches to hyperemesis during pregnancy.
Topics: Adrenal Cortex Hormones; Antiemetics; Diet; Doxylamine; Female; Humans; Hyperemesis Gravidarum; Obst | 2011 |
Reviewing the evidence for using continuous subcutaneous metoclopramide and ondansetron to treat nausea & vomiting during pregnancy.
Topics: Antiemetics; Evidence-Based Medicine; Female; Humans; Infusions, Subcutaneous; Metoclopramide; Nause | 2012 |
Nausea and vomiting of pregnancy.
Topics: Acupressure; Antiemetics; Diagnosis, Differential; Doxylamine; Female; Humans; Hyperemesis Gravidaru | 2003 |
[Cholestatic pruritus--pathophysiology and therapy with special reference to treatment with 5-hydroxytryptamine subtype 3 receptor antagonists].
Topics: Adult; Child; Cholestasis, Intrahepatic; Female; Humans; Indoles; Male; Nociceptors; Ondansetron; Pr | 1995 |
Management of chemotherapy in a pregnancy complicated by a large neuroblastoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Filgrastim; Gra | 1994 |
54 trials available for ondansetron and Pregnancy
| Article | Year |
|---|---|
Ondansetron and metoclopramide as second-line antiemetics in women with nausea and vomiting in pregnancy: the EMPOWER pilot factorial RCT.
Topics: Antiemetics; Cost-Benefit Analysis; Female; Humans; Metoclopramide; Nausea; Ondansetron; Pregnancy; | 2021 |
Intravenous ondansetron reduced nausea but not pruritus following intrathecal morphine in children: Interim results of a randomized, double-blinded, placebo-control trial.
Topics: Adult; Analgesics, Opioid; Cesarean Section; Child; Double-Blind Method; Female; Humans; Injections, | 2022 |
Low-dose esketamine with sufentanil for postcesarean analgesia in women with gestational diabetes mellitus: a prospective, randomized, double-blind study.
Topics: Analgesia; Diabetes, Gestational; Double-Blind Method; Female; Humans; Infant, Newborn; Ondansetron; | 2023 |
A Prospective, Randomized, Double-Blinded Study of the Effect of Intravenous Ondansetron on the Effective Dose in 50% of Subjects of Prophylactic Phenylephrine Infusions for Preventing Spinal Anesthesia-Induced Hypotension During Cesarean Delivery.
Topics: Adult; Anesthesia, Spinal; Antiemetics; Cesarean Section; Dose-Response Relationship, Drug; Double-B | 2020 |
Comparison of the Effects of Dexamethasone and Ondansetron on the Reduction of Postoperative Nausea and Vomiting following Cesarean Section under Spinal Anesthesia.
Topics: Anesthesia, Spinal; Cesarean Section; Dexamethasone; Female; Humans; Ondansetron; Postoperative Naus | 2021 |
Validating the effect of Ondansetron and Mirtazapine In Treating hyperemesis gravidarum (VOMIT): protocol for a randomised placebo-controlled trial.
Topics: Antiemetics; Female; Humans; Hyperemesis Gravidarum; Mirtazapine; Multicenter Studies as Topic; Onda | 2020 |
Prevention of postanesthetic shivering under subarachnoid block for cesarean section: A randomized, controlled study comparing tramadol versus ondansetron.
Topics: Adult; Analgesics, Opioid; Anesthesia, Obstetrical; Anesthesia, Spinal; Cesarean Section; Double-Bli | 2020 |
Does an Earlier or Late Intravenous Injection of Ondansetron Affect the Dose of Phenylephrine Needed to Prevent Spinal-Anesthesia Induced Hypotension in Cesarean Sections?
Topics: Adult; Anesthesia, Spinal; Cesarean Section; Dose-Response Relationship, Drug; Double-Blind Method; | 2020 |
Effect of gabapentin on hyperemesis gravidarum: a double-blind, randomized controlled trial.
Topics: Antiemetics; Female; Gabapentin; Humans; Hyperemesis Gravidarum; Infant, Newborn; Ondansetron; Pregn | 2021 |
Ondansetron versus ondansetron with dexamethasone to prevent intrathecal-morphine pruritus for caesarean patients: randomised double-blind trial.
Topics: Adult; Antipruritics; Cesarean Section; Dexamethasone; Double-Blind Method; Drug Therapy, Combinatio | 2021 |
Does prophylactic ondansetron reduce norepinephrine consumption in patients undergoing cesarean section with spinal anesthesia?
Topics: Administration, Intravenous; Adult; Anesthesia, Obstetrical; Anesthesia, Spinal; Cardiac Output; Ces | 2018 |
Minimal effective weight-based dosing of ondansetron to reduce hypotension in cesarean section under spinal anesthesia: a randomized controlled superiority trial.
Topics: Administration, Intravenous; Adult; Anesthesia, Spinal; Blood Loss, Surgical; Blood Pressure; Blood | 2018 |
Prophylactic Effects of Ephedrine, Ondansetron and Ringer on Hemodynamic Changes during Cesarean Section under Spinal Anesthesia - a randomized clinical trial.
Topics: Adrenergic Agonists; Adult; Anesthesia, Obstetrical; Anesthesia, Spinal; Arterial Pressure; Cesarean | 2018 |
Antiemetics added to phenylephrine infusion during cesarean delivery: a randomized controlled trial.
Topics: Adult; Anesthesia, Spinal; Antiemetics; Cardiotonic Agents; Cesarean Section; Drug Therapy, Combinat | 2013 |
Antiemetics added to phenylephrine infusion during cesarean delivery: a randomized controlled trial.
Topics: Adult; Anesthesia, Spinal; Antiemetics; Cardiotonic Agents; Cesarean Section; Drug Therapy, Combinat | 2013 |
Antiemetics added to phenylephrine infusion during cesarean delivery: a randomized controlled trial.
Topics: Adult; Anesthesia, Spinal; Antiemetics; Cardiotonic Agents; Cesarean Section; Drug Therapy, Combinat | 2013 |
Antiemetics added to phenylephrine infusion during cesarean delivery: a randomized controlled trial.
Topics: Adult; Anesthesia, Spinal; Antiemetics; Cardiotonic Agents; Cesarean Section; Drug Therapy, Combinat | 2013 |
Ondansetrone or metoclopromide? Which is more effective in severe nausea and vomiting of pregnancy? A randomized trial double-blind study.
Topics: Adult; Antiemetics; Double-Blind Method; Female; Humans; Hyperemesis Gravidarum; Metoclopramide; Ond | 2013 |
Antiemetic effects of dexamethasone and ondansetron combination during cesarean sections under spinal anaesthesia.
Topics: Adult; Anesthesia, Spinal; Antiemetics; Cesarean Section; Dexamethasone; Double-Blind Method; Drug T | 2013 |
Ondansetron preloading with crystalloid infusion reduces maternal hypotension during cesarean delivery.
Topics: Adult; Anesthesia, Obstetrical; Anesthesia, Spinal; Anti-Anxiety Agents; Blood Pressure; Carbon Diox | 2014 |
The effect of intravenous ondansetron on maternal haemodynamics during elective caesarean delivery under spinal anaesthesia: a double-blind, randomised, placebo-controlled trial.
Topics: Adult; Anesthesia, Obstetrical; Anesthesia, Spinal; Antiemetics; Blood Pressure; Cesarean Section; D | 2014 |
Ondansetron compared with metoclopramide for hyperemesis gravidarum: a randomized controlled trial.
Topics: Adult; Antiemetics; Female; Humans; Hyperemesis Gravidarum; Metoclopramide; Ondansetron; Pregnancy; | 2014 |
Prevention versus treatment of intrathecal morphine-induced pruritus with ondansetron.
Topics: Adult; Analgesics, Opioid; Anesthesia, Spinal; Antipruritics; Cesarean Section; Double-Blind Method; | 2014 |
Ondansetron compared with doxylamine and pyridoxine for treatment of nausea in pregnancy: a randomized controlled trial.
Topics: Adult; Antiemetics; Double-Blind Method; Doxylamine; Drug Therapy, Combination; Female; Follow-Up St | 2014 |
Dexamethasone versus a combination of dexamethasone and ondansetron as prophylactic antiemetic in patients receiving intrathecal morphine for caesarean section.
Topics: Adult; Analgesia, Obstetrical; Analgesics, Opioid; Antiemetics; Bupivacaine; Cesarean Section; Dexam | 2014 |
Ondansetron pharmacokinetics in pregnant women and neonates: towards a new treatment for neonatal abstinence syndrome.
Topics: Adult; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Administration Schedule; F | 2015 |
Effect of ondansetron on post-dural puncture headache (PDPH) in parturients undergoing cesarean section: a double-blind randomized placebo-controlled study.
Topics: Adult; Anesthesia, Spinal; Antiemetics; Cesarean Section; Double-Blind Method; Female; Humans; Hypot | 2015 |
Prophylactic administration of ondansetron in prevention of intrathecal morphine-induced pruritus and post-operative nausea and vomiting in patients undergoing caesarean section.
Topics: Adult; Analgesics, Opioid; Antiemetics; Cesarean Section; Double-Blind Method; Female; Humans; Morph | 2015 |
Prophylactic administration of ondansetron in prevention of intrathecal morphine-induced pruritus and post-operative nausea and vomiting in patients undergoing caesarean section.
Topics: Adult; Analgesics, Opioid; Antiemetics; Cesarean Section; Double-Blind Method; Female; Humans; Morph | 2015 |
Prophylactic administration of ondansetron in prevention of intrathecal morphine-induced pruritus and post-operative nausea and vomiting in patients undergoing caesarean section.
Topics: Adult; Analgesics, Opioid; Antiemetics; Cesarean Section; Double-Blind Method; Female; Humans; Morph | 2015 |
Prophylactic administration of ondansetron in prevention of intrathecal morphine-induced pruritus and post-operative nausea and vomiting in patients undergoing caesarean section.
Topics: Adult; Analgesics, Opioid; Antiemetics; Cesarean Section; Double-Blind Method; Female; Humans; Morph | 2015 |
The influence of intravenous ondansetron on maternal blood haemodynamics after spinal anaesthesia for caesarean section: a double-blind, placebo-controlled study.
Topics: Antiemetics; Blood Pressure; Cesarean Section; Dose-Response Relationship, Drug; Double-Blind Method | 2015 |
Randomized controlled trial comparing ondansetron and placebo for the reduction of spinal anesthesia-induced hypotension during elective cesarean delivery in Egypt.
Topics: Administration, Intravenous; Adult; Anesthesia, Spinal; Blood Pressure; Bradycardia; Cesarean Sectio | 2016 |
A randomized controlled trial of pentazocine versus ondansetron for the treatment of intrathecal morphine-induced pruritus in patients undergoing cesarean delivery.
Topics: Adult; Analgesia, Obstetrical; Analgesics, Opioid; Antipruritics; Cesarean Section; Double-Blind Met | 2009 |
Reduction of severity of pruritus after elective caesarean section under spinal anaesthesia with subarachnoid morphine: a randomised comparison of prophylactic granisetron and ondansetron.
Topics: Adult; Analgesics, Opioid; Anesthesia, Obstetrical; Anesthesia, Spinal; Cesarean Section; Double-Bli | 2010 |
Ondansetron is as effective as diphenhydramine for treatment of morphine-induced pruritus after cesarean delivery.
Topics: Adult; Cesarean Section; Diphenhydramine; Double-Blind Method; Female; Histamine H1 Antagonists; Hum | 2010 |
Effect of acupuncture on nausea and/or vomiting during and after cesarean section in comparison with ondansetron.
Topics: Acupuncture Therapy; Adult; Anesthesia, Obstetrical; Anesthesia, Spinal; Antiemetics; Cesarean Secti | 2011 |
Reduction in spinal-induced hypotension with ondansetron in parturients undergoing caesarean section: a double-blind randomised, placebo-controlled study.
Topics: Adult; Anesthesia, Obstetrical; Anesthesia, Spinal; Blood Pressure; Cesarean Section; Double-Blind M | 2012 |
Reduction in spinal-induced hypotension with ondansetron in parturients undergoing caesarean section: a double-blind randomised, placebo-controlled study.
Topics: Adult; Anesthesia, Obstetrical; Anesthesia, Spinal; Blood Pressure; Cesarean Section; Double-Blind M | 2012 |
Reduction in spinal-induced hypotension with ondansetron in parturients undergoing caesarean section: a double-blind randomised, placebo-controlled study.
Topics: Adult; Anesthesia, Obstetrical; Anesthesia, Spinal; Blood Pressure; Cesarean Section; Double-Blind M | 2012 |
Reduction in spinal-induced hypotension with ondansetron in parturients undergoing caesarean section: a double-blind randomised, placebo-controlled study.
Topics: Adult; Anesthesia, Obstetrical; Anesthesia, Spinal; Blood Pressure; Cesarean Section; Double-Blind M | 2012 |
Reduction in spinal-induced hypotension with ondansetron in parturients undergoing caesarean section: a double-blind randomised, placebo-controlled study.
Topics: Adult; Anesthesia, Obstetrical; Anesthesia, Spinal; Blood Pressure; Cesarean Section; Double-Blind M | 2012 |
Reduction in spinal-induced hypotension with ondansetron in parturients undergoing caesarean section: a double-blind randomised, placebo-controlled study.
Topics: Adult; Anesthesia, Obstetrical; Anesthesia, Spinal; Blood Pressure; Cesarean Section; Double-Blind M | 2012 |
Reduction in spinal-induced hypotension with ondansetron in parturients undergoing caesarean section: a double-blind randomised, placebo-controlled study.
Topics: Adult; Anesthesia, Obstetrical; Anesthesia, Spinal; Blood Pressure; Cesarean Section; Double-Blind M | 2012 |
Reduction in spinal-induced hypotension with ondansetron in parturients undergoing caesarean section: a double-blind randomised, placebo-controlled study.
Topics: Adult; Anesthesia, Obstetrical; Anesthesia, Spinal; Blood Pressure; Cesarean Section; Double-Blind M | 2012 |
Reduction in spinal-induced hypotension with ondansetron in parturients undergoing caesarean section: a double-blind randomised, placebo-controlled study.
Topics: Adult; Anesthesia, Obstetrical; Anesthesia, Spinal; Blood Pressure; Cesarean Section; Double-Blind M | 2012 |
Nalbuphine versus ondansetron for prevention of intrathecal morphine-induced pruritus after cesarean delivery.
Topics: Adult; Analgesics, Opioid; Cesarean Section; Double-Blind Method; Female; Humans; Morphine; Nalbuphi | 2003 |
Nalbuphine versus ondansetron for prevention of intrathecal morphine-induced pruritus after cesarean delivery.
Topics: Adult; Analgesics, Opioid; Cesarean Section; Double-Blind Method; Female; Humans; Morphine; Nalbuphi | 2003 |
Nalbuphine versus ondansetron for prevention of intrathecal morphine-induced pruritus after cesarean delivery.
Topics: Adult; Analgesics, Opioid; Cesarean Section; Double-Blind Method; Female; Humans; Morphine; Nalbuphi | 2003 |
Nalbuphine versus ondansetron for prevention of intrathecal morphine-induced pruritus after cesarean delivery.
Topics: Adult; Analgesics, Opioid; Cesarean Section; Double-Blind Method; Female; Humans; Morphine; Nalbuphi | 2003 |
Effects of the oral form of ondansetron on cerebellar dysfunction. A multi-center double-blind study.
Topics: Administration, Oral; Adolescent; Antiemetics; Cerebellar Diseases; Double-Blind Method; Drug Tolera | 2003 |
Intrathecal fentanyl-induced pruritus during labour: the effect of prophylactic ondansetron.
Topics: Adult; Analgesia, Obstetrical; Analgesics, Opioid; Double-Blind Method; Female; Fentanyl; Humans; In | 2004 |
Pre-emptive therapy for severe nausea and vomiting of pregnancy and hyperemesis gravidarum.
Topics: Adult; Antiemetics; Dicyclomine; Doxylamine; Drug Administration Schedule; Drug Combinations; Female | 2004 |
Ondansetron and tropisetron do not prevent intraspinal morphine- and fentanyl-induced pruritus in elective cesarean delivery.
Topics: Adult; Analgesics, Opioid; Anesthesia, Epidural; Anesthesia, Spinal; Anti-Inflammatory Agents, Non-S | 2006 |
Placental transfer of ondansetron during early human pregnancy.
Topics: Adult; Amniotic Fluid; Antiemetics; Body Fluids; Female; Fetus; Humans; Maternal-Fetal Exchange; Mod | 2006 |
Ondansetron or droperidol for prophylaxis of nausea and vomiting after intrathecal morphine.
Topics: Adult; Cesarean Section; Double-Blind Method; Droperidol; Female; Follow-Up Studies; Humans; Injecti | 2006 |
Does ondansetron or granisetron prevent subarachnoid morphine-induced pruritus after cesarean delivery?
Topics: Adult; Antipruritics; Cesarean Section; Female; Granisetron; Humans; Injections, Spinal; Morphine; O | 2007 |
Lornoxicam and ondansetron for the prevention of intrathecal fentanyl-induced pruritus.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antipruritics; Apgar Score; Cesarean Section; Double | 2007 |
Epidural ondansetron is more effective to prevent postoperative pruritus and nausea than intravenous ondansetron in elective cesarean delivery.
Topics: Adult; Analgesics, Opioid; Anesthesia, Epidural; Animals; Antiemetics; Cesarean Section; Female; Hum | 2007 |
Transdermal scopolamine for prevention of intrathecal morphine-induced nausea and vomiting after cesarean delivery.
Topics: Administration, Cutaneous; Analgesia, Obstetrical; Analgesics, Opioid; Antiemetics; Cesarean Section | 2007 |
Intraoperative antiemetic efficacy of prophylactic ondansetron versus droperidol for cesarean section patients under epidural anesthesia.
Topics: Adult; Anesthesia, Epidural; Anesthesia, Obstetrical; Antiemetics; Cesarean Section; Double-Blind Me | 1996 |
A pilot study of intravenous ondansetron for hyperemesis gravidarum.
Topics: Adult; Antiemetics; Double-Blind Method; Female; Humans; Hyperemesis Gravidarum; Injections, Intrave | 1996 |
Ondansetron is not superior to moderate dose metoclopramide in the prevention of post-operative nausea and vomiting after minor gynaecological surgery.
Topics: Adult; Antiemetics; Dilatation and Curettage; Double-Blind Method; Female; Gynecologic Surgical Proc | 1997 |
Evaluation of treatment of hyperemesis gravidarum using parenteral fluid with or without diazepam. A randomized study.
Topics: Adult; Antiemetics; Diazepam; Female; Gestational Age; Humans; Hydrocortisone; Hyperemesis Gravidaru | 1999 |
Intrathecal fentanyl is superior to intravenous ondansetron for the prevention of perioperative nausea during cesarean delivery with spinal anesthesia.
Topics: Adjuvants, Anesthesia; Adult; Analgesics, Opioid; Anesthesia, Obstetrical; Anesthesia, Spinal; Antie | 2000 |
Prophylactic intravenous ondansetron reduces the incidence of intrathecal morphine-induced pruritus in patients undergoing cesarean delivery.
Topics: Adolescent; Adult; Analgesia, Obstetrical; Analgesics, Opioid; Anesthesia, Spinal; Anesthetics, Loca | 2000 |
Prophylactic intravenous ondansetron reduces the incidence of intrathecal morphine-induced pruritus in patients undergoing cesarean delivery.
Topics: Adolescent; Adult; Analgesia, Obstetrical; Analgesics, Opioid; Anesthesia, Spinal; Anesthetics, Loca | 2000 |
Prophylactic intravenous ondansetron reduces the incidence of intrathecal morphine-induced pruritus in patients undergoing cesarean delivery.
Topics: Adolescent; Adult; Analgesia, Obstetrical; Analgesics, Opioid; Anesthesia, Spinal; Anesthetics, Loca | 2000 |
Prophylactic intravenous ondansetron reduces the incidence of intrathecal morphine-induced pruritus in patients undergoing cesarean delivery.
Topics: Adolescent; Adult; Analgesia, Obstetrical; Analgesics, Opioid; Anesthesia, Spinal; Anesthetics, Loca | 2000 |
Ondansetron versus placebo for the control of nausea and vomiting during Caesarean section under spinal anaesthesia.
Topics: Adult; Anesthesia, Obstetrical; Anesthesia, Spinal; Antiemetics; Cesarean Section; Double-Blind Meth | 1999 |
Ondansetron versus placebo for the control of nausea and vomiting during Caesarean section under spinal anaesthesia.
Topics: Adult; Anesthesia, Obstetrical; Anesthesia, Spinal; Antiemetics; Cesarean Section; Double-Blind Meth | 1999 |
Ondansetron versus placebo for the control of nausea and vomiting during Caesarean section under spinal anaesthesia.
Topics: Adult; Anesthesia, Obstetrical; Anesthesia, Spinal; Antiemetics; Cesarean Section; Double-Blind Meth | 1999 |
Ondansetron versus placebo for the control of nausea and vomiting during Caesarean section under spinal anaesthesia.
Topics: Adult; Anesthesia, Obstetrical; Anesthesia, Spinal; Antiemetics; Cesarean Section; Double-Blind Meth | 1999 |
Prophylactic ondansetron does not improve patient satisfaction in women using PCA after Caesarean section.
Topics: Analgesia, Patient-Controlled; Analgesics, Opioid; Anesthesia, Obstetrical; Anesthesia, Spinal; Anti | 2001 |
Comparing the efficacy of prophylactic metoclopramide, ondansetron, and placebo in cesarean section patients given epidural anesthesia.
Topics: Adult; Anesthesia, Epidural; Anesthesia, Obstetrical; Antiemetics; Cesarean Section; Double-Blind Me | 2001 |
Prophylactic ondansetron is effective in the treatment of nausea and vomiting but not on pruritus after cesarean delivery with intrathecal sufentanil-morphine.
Topics: Adult; Anesthesia, Obstetrical; Antiemetics; Bupivacaine; Cesarean Section; Double-Blind Method; Fem | 2002 |
Ondansetron in the treatment of postoperative vomiting: a randomized, double-blind comparison with droperidol and metoclopramide.
Topics: Adult; Anesthesia, General; Anesthesia, Obstetrical; Antiemetics; Dilatation and Curettage; Double-B | 1992 |
90 other studies available for ondansetron and Pregnancy
| Article | Year |
|---|---|
[Nausea and vomiting in pregnancy: A place for ondansetron?]
Topics: Antiemetics; Cleft Lip; Cleft Palate; Female; Humans; Nausea; Ondansetron; Pregnancy; Vomiting | 2021 |
A pharmacogenomic investigation of the cardiac safety profile of ondansetron in children and pregnant women.
Topics: Antiemetics; Child; Female; Genome-Wide Association Study; Humans; Nausea; Ondansetron; Pregnancy; P | 2022 |
Ondansetron use in nausea and vomiting during pregnancy: A descriptive analysis of prescription patterns and patient characteristics in UK general practice.
Topics: Antiemetics; Female; Folic Acid; General Practice; Humans; Nausea; Ondansetron; Pregnancy; Pregnancy | 2022 |
Safety evaluation of ondansetron after gestational exposure on male reproductive parameters in rats.
Topics: Animals; Body Weight; Female; Humans; Male; Maternal Exposure; Ondansetron; Pregnancy; Prenatal Expo | 2023 |
Safety evaluation of ondansetron after gestational exposure on male reproductive parameters in rats.
Topics: Animals; Body Weight; Female; Humans; Male; Maternal Exposure; Ondansetron; Pregnancy; Prenatal Expo | 2023 |
Safety evaluation of ondansetron after gestational exposure on male reproductive parameters in rats.
Topics: Animals; Body Weight; Female; Humans; Male; Maternal Exposure; Ondansetron; Pregnancy; Prenatal Expo | 2023 |
Safety evaluation of ondansetron after gestational exposure on male reproductive parameters in rats.
Topics: Animals; Body Weight; Female; Humans; Male; Maternal Exposure; Ondansetron; Pregnancy; Prenatal Expo | 2023 |
Embryo-fetal safety evaluation of ondansetron in rats.
Topics: Animals; Antiemetics; Embryo, Mammalian; Female; Nausea; Ondansetron; Pregnancy; Rats; Vomiting | 2023 |
Ondansetron Use During Pregnancy: Birth Defects and Obstetric Outcomes.
Topics: Antiemetics; Female; Humans; Hyperemesis Gravidarum; Infant, Newborn; Nausea; Ondansetron; Pregnancy | 2023 |
How safe and effective is ondansetron for nausea and vomiting in pregnancy?
Topics: Antiemetics; Female; Humans; Morning Sickness; Ondansetron; Pregnancy | 2019 |
Intravenous Ondansetron in Pregnancy and Risk of Congenital Malformations.
Topics: Abnormalities, Drug-Induced; Administration, Oral; Adult; Antiemetics; Cleft Lip; Cleft Palate; Fema | 2020 |
Ondansetron use in the first trimester of pregnancy and the risk of neonatal ventricular septal defect.
Topics: Female; Heart Septal Defects, Ventricular; Humans; Infant, Newborn; Ondansetron; Pregnancy; Pregnanc | 2020 |
Ondansetron Use in Pregnancy and Congenital Malformations.
Topics: Abnormalities, Drug-Induced; Administration, Intravenous; Antiemetics; Female; Humans; Ondansetron; | 2020 |
Ondansetron Use in Pregnancy and Congenital Malformations-Reply.
Topics: Abnormalities, Drug-Induced; Antiemetics; Female; Humans; Ondansetron; Pregnancy | 2020 |
Protection Versus Progress: The Challenge of Research on Cannabis Use During Pregnancy.
Topics: Antiemetics; Dicyclomine; Doxylamine; Drug Approval; Drug Combinations; Ethics, Research; Female; Hu | 2020 |
5-HT3 blockade does not attenuate postspinal blood pressure change in cesarean section: A case-control study.
Topics: Adult; Anesthesia, Obstetrical; Anesthesia, Spinal; Apgar Score; Arterial Pressure; Case-Control Stu | 2020 |
Ondansetron should never be used in pregnancy.
Topics: Antiemetics; Congenital Abnormalities; Female; Humans; Hyperemesis Gravidarum; Ondansetron; Pregnanc | 2021 |
Ondansetron should never be used in pregnancy: Against: Ondansetron in pregnancy revisited.
Topics: Antiemetics; Congenital Abnormalities; Female; Humans; Hyperemesis Gravidarum; Ondansetron; Pregnanc | 2021 |
Ondansetron use in early pregnancy and the risk of miscarriage.
Topics: Abortion, Spontaneous; Antiemetics; Female; Humans; Metoclopramide; Ondansetron; Pregnancy; Vomiting | 2021 |
Ondansetron use in early pregnancy and the risk of late pregnancy outcomes.
Topics: Antiemetics; Female; Humans; Infant, Newborn; Ondansetron; Pregnancy; Pregnancy Outcome; Premature B | 2021 |
Pregnancy outcome following in-utero exposure to ondansetron: A prospective comparative observational study.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Antiemetics; Child; Child, Preschool; Female; Heart | 2021 |
Ondansetron in pregnancy revisited: Assessment and pregnancy labelling by the European Medicines Agency (EMA) & Pharmacovigilance Risk Assessment Committee (PRAC).
Topics: Antiemetics; Cleft Lip; Cleft Palate; Contraindications, Drug; Drug Labeling; European Union; Female | 2021 |
Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trial.
Topics: Antiemetics; Cannabis; Female; Haloperidol; Humans; Hyperemesis Gravidarum; Ondansetron; Pregnancy; | 2021 |
A case of paradoxical presentation of a postural postdural puncture headache after combined spinal-epidural anesthesia.
Topics: Acetaminophen; Adult; Analgesics, Opioid; Anesthesia, Epidural; Anesthesia, Obstetrical; Anesthesia, | 2017 |
A Physiologically Based Pharmacokinetic Model for Pregnant Women to Predict the Pharmacokinetics of Drugs Metabolized Via Several Enzymatic Pathways.
Topics: Caffeine; Cytochrome P-450 Enzyme System; Diazepam; Female; Granisetron; Humans; Metoprolol; Metroni | 2018 |
Pityriasis rosea-like eruption associated with ondansetron use in pregnancy.
Topics: Adult; Antiemetics; Female; Humans; Ondansetron; Pityriasis Rosea; Pregnancy; Pregnancy Complication | 2018 |
Do fetuses need vasopressors just before their birth?
Topics: Anesthesia, Obstetrical; Anesthesia, Spinal; Cesarean Section; Female; Fetus; Humans; Norepinephrine | 2018 |
Ondansetron for Treatment of Nausea and Vomiting of Pregnancy and the Risk of Specific Birth Defects.
Topics: Abnormalities, Drug-Induced; Adult; Antiemetics; Case-Control Studies; Drug Administration Schedule; | 2018 |
Ondansetron and teratogenicity in rats: Evidence for a mechanism mediated via embryonic hERG blockade.
Topics: Abnormalities, Drug-Induced; Animals; Antiemetics; Cardiovascular Abnormalities; Embryo, Mammalian; | 2018 |
Comment on: Ondansetron in Pregnancy and the Risk of Congenital Malformations: A Systematic Review.
Topics: Abnormalities, Drug-Induced; Antiemetics; Female; Humans; Ondansetron; Pregnancy | 2018 |
First trimester ondansetron exposure and risk of structural birth defects.
Topics: Adult; Antiemetics; Congenital Abnormalities; Female; Humans; Male; Maternal-Fetal Exchange; Odds Ra | 2019 |
Getting through the day: a pilot qualitative study of U.S. women's experiences making decisions about anti-nausea medication during pregnancy.
Topics: Adolescent; Adult; Antiemetics; Decision Making; Female; Focus Groups; Humans; Morning Sickness; Ond | 2018 |
Helping Pregnant Women and Clinicians Understand the Risk of Ondansetron for Nausea and Vomiting During Pregnancy.
Topics: Cleft Palate; Female; Humans; Nausea; Ondansetron; Pregnancy; Risk; Vomiting | 2018 |
Association of Maternal First-Trimester Ondansetron Use With Cardiac Malformations and Oral Clefts in Offspring.
Topics: Abnormalities, Drug-Induced; Adult; Antiemetics; Cleft Lip; Cleft Palate; Female; Heart Defects, Con | 2018 |
Gaining Insight Into Ondansetron Safety in Early Pregnancy.
Topics: Antiemetics; Female; Humans; Hyperemesis Gravidarum; Ondansetron; Pregnancy; Pregnancy Trimester, Fi | 2019 |
Anaphylactoid Syndrome of Pregnancy.
Topics: Adult; Antipruritics; Atropine; Cyclooxygenase Inhibitors; Female; Humans; Hypotension; IgA Vasculit | 2019 |
New evidence for concern over the risk of birth defects from medications for nausea and vomitting of pregnancy.
Topics: Abnormalities, Drug-Induced; Adult; Antiemetics; Cohort Studies; Dicyclomine; Doxylamine; Drug Combi | 2019 |
Ondansetron in pregnancy and risk of adverse fetal outcomes.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adult; Antiemetics; Female; Fetus; Humans; Infan | 2013 |
Ondansetron looks safe in pregnancy, so far.
Topics: Antiemetics; Female; Humans; Morning Sickness; Ondansetron; Pregnancy; Pregnancy Outcome; Pregnancy | 2013 |
Pharmacogenetic predictors of nausea and vomiting of pregnancy severity and response to antiemetic therapy: a pilot study.
Topics: Adult; Antiemetics; Female; Humans; Metoclopramide; Morning Sickness; Ondansetron; Pilot Projects; P | 2013 |
Accidental underdosing of intrathecal diamorphine.
Topics: Analgesics, Opioid; Antiemetics; Cesarean Section; Female; Heroin; Humans; Ondansetron; Pregnancy | 2013 |
Off-label use of ondansetron in pregnancy in Western Australia.
Topics: Adult; Antiemetics; Congenital Abnormalities; Female; Humans; Hyperemesis Gravidarum; Infant, Newbor | 2013 |
Antiemetic medications in pregnancy: a prospective investigation of obstetric and neurobehavioral outcomes.
Topics: Adult; Antiemetics; Child Development; Female; Humans; Infant, Newborn; Longitudinal Studies; Male; | 2014 |
Ventricular tachycardia associated with ondansetron and phenylephrine administration during spinal anaesthesia in pregnancy.
Topics: Adult; Anesthesia, Obstetrical; Anesthesia, Spinal; Antiemetics; Cesarean Section; Electrocardiograp | 2014 |
Drug treatment of adults with nausea and vomiting in primary care.
Topics: Adult; Antiemetics; Domperidone; Droperidol; Female; Histamine Antagonists; Humans; Male; Metoclopra | 2014 |
Treating morning sickness in the United States--changes in prescribing are needed.
Topics: Antiemetics; Dicyclomine; Doxylamine; Drug Approval; Drug Combinations; Female; Heart Defects, Conge | 2014 |
Use of ondansetron during pregnancy and congenital malformations in the infant.
Topics: Abnormalities, Drug-Induced; Antiemetics; Female; Heart Septal Defects; Humans; Infant, Newborn; Mal | 2014 |
Intestinal obstruction in pregnancy by ondansetron.
Topics: Adult; Antiemetics; Female; Humans; Intestinal Obstruction; Ondansetron; Pregnancy; Serotonin Antago | 2014 |
5-HT3 receptor antagonists do not alter spontaneous contraction of pregnant myometrium in vitro.
Topics: Female; Granisetron; Humans; In Vitro Techniques; Indoles; Ondansetron; Pregnancy; Serotonin Antagon | 2015 |
Ondansetron compared with doxylamine and pyridoxine for treatment of nausea in pregnancy: a randomized controlled trial.
Topics: Doxylamine; Female; Humans; Morning Sickness; Ondansetron; Pregnancy; Pyridoxine | 2015 |
Odansetron compared with doxylamine and pyridoxine for treatment of nausea in pregnancy: a randomized controlled trial.
Topics: Doxylamine; Female; Humans; Morning Sickness; Ondansetron; Pregnancy; Pyridoxine | 2015 |
In reply.
Topics: Doxylamine; Female; Humans; Morning Sickness; Ondansetron; Pregnancy; Pyridoxine | 2015 |
Comparison of antiemetics for nausea and vomiting of pregnancy in an emergency department setting.
Topics: Adult; Antiemetics; Cohort Studies; Emergency Service, Hospital; Female; Humans; Hypotension, Orthos | 2015 |
Intestinal obstruction is a rare complication of ondansetron exposure in hyperemesis gravidarum.
Topics: Antiemetics; Female; Humans; Intestinal Obstruction; Ondansetron; Pregnancy; Serotonin Antagonists | 2015 |
Fluctuating serum aspartate aminotransferase activity in a complicated pregnancy.
Topics: Adult; Alanine Transaminase; Antiemetics; Aspartate Aminotransferases; Clinical Enzyme Tests; Female | 2015 |
Ephedrine versus ondansetron in the prevention of hypotension during cesarean delivery: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Blood Pressure; Cesarean Section; Double-Blind Method; Ephedrine; Female; Humans; Hypotension | 2016 |
Ondansetron Use in Pregnancy.
Topics: Antiemetics; Female; Humans; Hyperemesis Gravidarum; Ondansetron; Pregnancy; Prenatal Care | 2016 |
Ondansetron in pregnancy and risk of adverse fetal outcomes in the United States.
Topics: Abortion, Spontaneous; Adolescent; Adult; Antiemetics; Child; Congenital Abnormalities; Female; Huma | 2016 |
Ondansetron and pregnancy: possible congenital heart defects.
Topics: Female; Heart Defects, Congenital; Humans; Ondansetron; Pregnancy; Serotonin 5-HT3 Receptor Antagoni | 2016 |
Ondansetron Exposure Changes in a Pregnant Woman.
Topics: Adult; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Female; Humans; Ondansetron; Pregnancy | 2016 |
Ondansetron Use in Pregnancy andOndansetron Use in Pregnancy and Birth Defects: A Systematic Review.
Topics: Antiemetics; Female; Humans; Hyperemesis Gravidarum; Ondansetron; Pregnancy | 2016 |
Inadvertent spinal injection of ondansetron.
Topics: Adult; Analgesics, Opioid; Anesthesia, Spinal; Cesarean Section; Female; Humans; Injections, Spinal; | 2016 |
Ondansetron in pregnancy and risk of adverse fetal outcomes in the United States.
Topics: Antiemetics; Female; Fetus; Humans; Ondansetron; Pregnancy; Prenatal Care; United States | 2016 |
Response to the questions submitted by Mr. Reichmann.
Topics: Female; Fetus; Humans; Ondansetron; Pregnancy; Prenatal Care; United States | 2016 |
Antiemetic use among pregnant women in the United States: the escalating use of ondansetron.
Topics: Adult; Algorithms; Antiemetics; Female; Humans; Morning Sickness; Ondansetron; Pilot Projects; Pract | 2017 |
Abolishment of serotonergic neurotransmission to cardiac vagal neurons during and after hypoxia and hypercapnia with prenatal nicotine exposure.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Action Potentials; Animals; Animals, Newborn; Conotoxins; Dose | 2009 |
A case study approach to Hyperemesis Gravidarum: home care implications.
Topics: Adult; Dehydration; Female; Fluid Therapy; Follow-Up Studies; Humans; Hyperemesis Gravidarum; Ondans | 2009 |
Ondansetron-induced headache in a parturient mimicking postdural puncture headache.
Topics: Adult; Antiemetics; Cesarean Section; Diagnostic Errors; Female; Headache; Humans; Ondansetron; Post | 2010 |
Granisetron or ondansetron for prevention of subarachnoid morphine-induced pruritus after cesarean delivery.
Topics: Adult; Analgesics, Opioid; Antiemetics; Antipruritics; Cesarean Section; Female; Granisetron; Humans | 2010 |
A newborn with Pierre Robin sequence after preconceptional mitoxantrone exposure of a female with multiple sclerosis.
Topics: Abnormalities, Drug-Induced; Adult; Antiemetics; Antineoplastic Agents; Female; Humans; Infant, Newb | 2011 |
Treatment of severe nausea and vomiting of pregnancy with subcutaneous medications.
Topics: Adolescent; Adult; Antiemetics; Female; Home Infusion Therapy; Humans; Infusions, Subcutaneous; Meto | 2011 |
Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects.
Topics: Abnormalities, Drug-Induced; Adult; Case-Control Studies; Cleft Lip; Cleft Palate; Female; Humans; H | 2012 |
Ondansetron use during pregnancy: a case series.
Topics: Adult; Antiemetics; Evidence-Based Medicine; Female; Humans; Hyperemesis Gravidarum; Ondansetron; Pr | 2012 |
Reduction in spinal-induced hypotension with ondansetron.
Topics: Anesthesia, Obstetrical; Anesthesia, Spinal; Female; Humans; Hypotension; Ondansetron; Pregnancy; Se | 2012 |
Can early post-spinal heart rate predict subsequent nausea during anaesthesia for caesarean section?
Topics: Adrenergic alpha-1 Receptor Agonists; Adult; Analgesics, Opioid; Anesthesia, Obstetrical; Anesthesia | 2012 |
Motherisk update. Is ondansetron safe for use during pregnancy?
Topics: Antiemetics; Canada; Cleft Palate; Female; Fetus; Humans; Long QT Syndrome; Morning Sickness; Nausea | 2012 |
The effect of ondansetron and intrathecal diamorphine on length of stay after caesarean section: an impact audit cycle.
Topics: Adult; Analgesics, Opioid; Anesthesia, Obstetrical; Antiemetics; Cesarean Section; Female; Heroin; H | 2013 |
A survey of prescribing for the management of nausea and vomiting in pregnancy in Australasia.
Topics: Antiemetics; Australia; Dopamine Antagonists; Female; Histamine Antagonists; Humans; Hyperemesis Gra | 2013 |
Treatment of intractable hyperemesis gravidarum by ondansetron.
Topics: Adult; Antiemetics; Cesarean Section; Diabetes, Gestational; Female; Gestational Age; Hospitalizatio | 2002 |
Ondansetron for prevention of intrathecal opioids-induced pruritus, nausea and vomiting after cesarean delivery.
Topics: Adult; Analgesics, Opioid; Antiemetics; Cesarean Section; Female; Humans; Morphine; Ondansetron; Pos | 2004 |
Cholestasis of pregnancy, pruritus and 5-hydroxytryptamine 3 receptor antagonists.
Topics: Cesarean Section; Cholestasis, Intrahepatic; Dose-Response Relationship, Drug; Female; Follow-Up Stu | 2004 |
The safety of ondansetron for nausea and vomiting of pregnancy: a prospective comparative study.
Topics: Adult; Analysis of Variance; Antiemetics; Female; Humans; Nausea; Ondansetron; Pregnancy; Pregnancy | 2004 |
Ondansetron-induced extrapyramidal symptoms during cesarean section.
Topics: Adult; Anesthesia, Obstetrical; Antiemetics; Basal Ganglia Diseases; Cesarean Section; Female; Human | 2005 |
Determinants of drug brain uptake in a rat model of seizure-associated malformations of cortical development.
Topics: Animals; Anticonvulsants; Astrocytes; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood | 2006 |
Preventing recurrence of severe morning sickness.
Topics: Antiemetics; Dicyclomine; Doxylamine; Drug Combinations; Female; Humans; Morning Sickness; Ondansetr | 2006 |
[Antinociceptive properties of the 5-HT3 receptor antagonist in the model of inflammatory pain in rats of different age with prenatal deficit of serotonine and under stress].
Topics: Aging; Analgesics; Animals; Female; Inflammation; Male; Ondansetron; Pain; Phenylalanine; Pregnancy; | 2007 |
Neonatal extrapyramidal movements. Neonatal withdrawal due to maternal citalopram and ondansetron use.
Topics: Adult; Anti-Anxiety Agents; Basal Ganglia Diseases; Citalopram; Female; Humans; Infant, Newborn; Lor | 2008 |
Ondansetron and hyperemesis gravidarum.
Topics: Adult; Female; Humans; Hyperemesis Gravidarum; Nephritis; Ondansetron; Pregnancy; Pregnancy Complica | 1993 |
Ondansetron for the treatment of pruritus after spinal opioids.
Topics: Anesthesia, Obstetrical; Anesthesia, Spinal; Cesarean Section; Female; Humans; Morphine; Ondansetron | 1996 |
Treatment of hyperemesis gravidarum with the 5-HT3 antagonist ondansetron (Zofran).
Topics: Adult; Antiemetics; Female; Humans; Hyperemesis Gravidarum; Ondansetron; Pregnancy; Pregnancy Trimes | 1996 |
Regulation of gene expression in cultured embryonic mouse mandibular mesenchyme by serotonin antagonists.
Topics: Aggrecans; Animals; Calcium-Binding Proteins; Chondroitin Sulfate Proteoglycans; Culture Techniques; | 1997 |
Ondansetron after Caesarian section.
Topics: Antiemetics; Breast Feeding; Cesarean Section; Female; Humans; Ondansetron; Postoperative Nausea and | 2001 |
Ondansetron and hyperemesis gravidarum.
Topics: Adult; Female; Humans; Hyperemesis Gravidarum; Ondansetron; Pregnancy | 1992 |